




A DERIVATIZATION PROTOCOL FOR MYCOLIC ACIDS DETECTION USING 







Paulina Zurita Urrea 
 





In partial fulfillment of the requirements 
 
For the Degree of Master of Science 
 
Colorado State University 
 









 Advisor:  John T. Belisle 
  
 Robert Jones 
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LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY 
 
New tools for the diagnosis and control of Tuberculosis are major challenges. 
In this context the use of biomarkers can be applied for detecting characteristic 
signatures from the tuberculosis-infected host and the pathogen. Mycolic acids are 
considered as a hallmark of the Mycobacterium genus being abundant in the 
mycobacterial cell wall.  In this study a derivatization protocol was tested to enhance 
the detection of mycolic acid after the attachment of a quaternary amine and analysis 
of the derivatized products in the positive ionization mode with liquid 
chromatography/mass spectrometry. Three groups were considered i) mycolic acid 
standard ii) human urine spiked with mycolic acid standard, and iii) human serum 
spiked with mycolic acid standard. Each group included the analysis of a set of non-
derivatized mycolic acids in positive and negative ionization mode, and derivatized 
mycolic acids in positive mode. The derivatization process applied to the mycolic 
acid standard and to the urine samples spiked with mycolic did not improve the ion 
volume value compared to the respective non-derivatized samples.  Serum samples, 
however, showed a significant enhancement in the ion volume of the different 
mycolic acids analyzed compared to the non-derivatized serum samples (α=0.05). 
The method detection limit for the three groups was also achieved. Urine and serum 
samples spiked with mycolic acids showed higher detection limits compared to the 
mycolic acid standard; this was expected due the lipid extraction protocol and the 
complex nature of these fluids. The derivatization protocol did not improve the 
method detection limit compared to the non-derivatized samples. The overall results 
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make the derivatization protocol questionable to be applied routinely in biological 
samples. However, the results obtained after the derivatization of serum samples 
could point to the advantages of using a derivatization protocol to study possible 
interactions between mycolic acids and other molecules present in serum that could 
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The genus Mycobacterium belongs to the order Actinomycetales, family 
Mycobacteriaceae and is comprised of the Mycobacterium tuberculosis complex 
(MTBC), Mycobacterium leprae and the nontuberculous mycobacteria (NTM). The 
MTBC includes Mycobacterium tuberculosis (Mtb), Mycobacterium africanum, 
Mycobacterium canettii, Mycobacterium bovis, Mycobacterium pinnipedii, 
Mycobacterium caprae and Mycobacterium microti. The NTM are represented by 
several species such as Mycobacterium avium complex (MAC) comprised of M. 
intracellulare and M. avium and the four subspecies included into M. avium: avium, 
hominissuis, silvaticum, paratuberculosis and intracellulare. Other NTM with clinical 
significance are Mycobacterium fortuitum, Mycobacterium kansasii, Mycobacterium 
marinum, Mycobacterium ulcerans and Mycobacterium scrofulaceum (Olsen et al., 
2010). 
 
1.1 Epidemiology of mycobacterial infections 
1.1.1 The Mycobacterium tuberculosis complex 
The mycobacteria belonging to the MTBC have a 99.9% similarity at the 
nucleotide level. However, they differ in their host tropism and pathogenicity. Mtb, M. 
africanum and M. canettii affect almost exclusively humans, while M. microti is a 
rodent pathogen (Brosch et al., 2002), and M. bovis has a broad host spectrum. Two 
new species with a zoonotic character have been included in the MTBC, M. pinnipidii 
has been reported in fur seals and sea lions (Thoen et al., 2009) and M. caprae is 
primarily isolated from goats, but is also a common source of bovine tuberculosis 




The MTBC has been proposed to derive from a pool of ancestral tubercle 
bacilli, collectively called ‗‗Mycobacterium prototuberculosis’’. Genetic studies link the 
migration of population from east Africa, 40,000 years ago, with the propagation of 
the most common ancestor, M. canettii, followed by the radiation of two major 
lineages, one of which was disseminated from humans to animals (Wirth et al., 
2008).  
M. bovis was hypothesized to be the origin of human TB, based on its broader 
host range. However, several genome deletions in M. bovis relative to Mtb have 
been shown, indicating a smaller genome, pointing to Mtb as the ancestor of 
M.bovis. The DNA loss in M. bovis could explain the clonal expansion of the bacteria 
linked to the success of this pathogen in new hosts (Brosch et al., 2002). 
M. bovis causes a zoonotic disease identified in humans in several countries, 
and affecting in a higher proportion people related to farms and slaughterhouses. 
Bovine TB eradication programs have reduced the disease and death by M. bovis in 
human population (OIE, 2009). Despite the fact that cattle are considered the true 
hosts of M. bovis, the disease has been reported in several domesticated and non-
domesticated animals. Examples of TB in wildlife include ungulates such as the 
African buffalo (Syncerus caffer) and the North American bison (Bison bison) as 
major reservoirs of the pathogen. European badgers (Meles meles) in the United 
Kingdom, brushtail possums (Trichosurus vulpecula) in New Zealand and several 
cervids species are also recognized reservoirs of M. bovis (Thoen et al., 2009). 
Mtb, isolated for the first time in 1882 by Robert Koch, is the most common 
mycobacterium spp. That causes disease (Wagner el al, 2004) and is the second 
cause of death from an infectious disease worldwide. According to the World Health 
Organization (WHO), one third of the world population is currently infected, 
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estimating 9.4 million TB incident cases for 2010 (estimated from predict values from 
2006–2009) and localized principally in South-East Asia, Africa and Western Pacific 
regions (WHO, 2010).  
Primary infection with Mtb produces an active disease in a small proportion of 
the population; only 5 to 10% of recently exposed individuals develop clinically active 
TB during the first 2 years after exposure (Demissie et al., 2006). However, a higher 
percentage of exposed individuals can contain the infection and develop latent TB. 
This latency state, characterized as symptom-free and non-infectious can persist 
during all the lifetime of the individual or can reactivate because of different causes; 
such as human immunodeficiency virus (HIV) infection, malnutrition, advanced age, 
immunosuppressive medication, or other situations that overall affect the immune 
response of the individual (Tufariello et al., 2003). 
One of the central strategies of WHO is to combat TB trough a directly 
observed treatment short course (DOTS). A pivotal component of the DOTS program 
is the diagnosis of active TB by sputum smear microscopy (WHO, 2010). Despite the 
availability of treatment and the high rate of cure, a major difficulty in fighting this 
disease is the case detection rate (CDR). In 2009 the CDR was 63% (range 60-
67%), with the highest rates in the European region (WHO, 2010) and the lowest 
level in the African region with a rate of 50% (WHO, 2010). The consequences of the 
CDR are reflected in a delayed start of treatment, affecting the prognosis of the 
patients, perpetuating the contact rate case, and fomenting the propagation of the 
disease (McNerney et al., 2011). 
Immunosuppressed individuals and children often have a different clinical 
pattern compared to immunocompetent adults, resulting in poor sensitivity for the 
smear microscopy test (McNerney et al., 2011). Fewer acid-fast bacilli (AFB) in the 
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sputum of HIV-infected persons makes the smear microscopy less reliable (Samb et 
al., 1999). The diagnosis of childhood TB represents a major challenge in terms of 
having an appropriate diagnostic sample and test. Children usually do not produce 
sputum, and gastric aspirates can be collected for smear microscopy. However, 
detection is less than 20% when sputum or gastric aspirates are used (Shingadia et 
al., 2003). The culture of Mtb is also limited for clinical samples from children 
because of the paucibacillary characteristics of the disease in this population group 
(Marais et al., 2006). Infection in children has been categorized as a sentinel event 
or proof of the ongoing transmission of the disease in a population. Unrecognized 
cases without therapy become an important and long-term reservoir of TB in the 
population (Smith, 2001). 
 
1.1.2 The nontuberculous mycobacteria and Leprosy 
Approximately 50 NTM species are considered to be etiological agents of 
human disease, naturally inhabiting environmental sources such as soil and drinking 
water. Animals can also serve as reservoirs of NTM (Wagner et al., 2004). The 
traditional Runyon system groups the NTM according to their growth rates as slow 
growers (groups I to III) and rapid growers (group IV). Slow growers are also 
subdivided based on their pigment production in group I photochromogens (pigment 
producers in the presence of light), group II scoto-chromogens (pigment producers in 
the absence of light), and group III non-chromogens (Jarzembowski et al., 2008). For 
the diagnosis of NTM different tools are available. High performance liquid 
chromatography allows rapid identification by the analysis of mycolic acids (Butler et 
al., 2001). Commercial DNA probes (AccuProbe; Gen-Probe Inc.) contain a 
chemiluminescent label and hybridize with the complementary ribosomal RNA of the 
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target organism. They are available for the identification of M. avium, M. 
intracellulare, MAC, M. kansasii and M. gordonae. Samples that cannot be identified 
with the mentioned methods can be analyzed using 16 rRNA gene sequencing. The 
advantages of using this gene are that it is present in all bacterial species and 
contains variable and conserved regions. By sequencing two of the hypervariable 
regions, the majority of the mycobacterial species can be identified (Soini et al 2001). 
As a result of the HIV epidemic, NTM infections increased, showing a 
disseminated clinical process. However, after the introduction of the highly active 
antiretroviral therapy (HAART) for HIV there was a notorious rate decline of all 
opportunistic infections, including NTM. Currently, NTM affect non-treated or 
treatment failure HIV patients and also can appear during the early period of HAART, 
before the immune recovery. Other conditions that can predispose individuals to 
NTM infections are chronic obstructive pulmonary disease and cystic fibrosis 
(Gopinath et al., 2010). NTM infections can present as pulmonary disease, 
lymphadenitis, skin and soft tissue disease, skeletal infection, and disseminated 
infection (Wagner and Young, 2004). M. avium and M. intracellulare, members of the 
MAC, are the most common cause of NTM in AIDS patients (Jones et al., 2002). M. 
ulcerans, included in the NTM group, is the third major mycobacterial disease of 
humans (Wagner el al, 2004). It produces the toxin mycolactone that leads to the 
destruction of the subcutaneous adipose tissue and subsequent formation of a 
characteristic ulcer (Demangel et al., 2009). 
NTM can be underestimated in endemic TB countries, mainly because of the 
lack of a reporter system and proper infrastructure for their identification (Gopinath et 
al., 2010). Treatment of NTM pulmonary infection includes long-term therapy. For M. 
avium and M. intracellulare at least three drugs are recommended to avoid the 
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emergence of resistance. Macrolides are always included because of their 
effectiveness (Jarzembowski et al., 2008).   
M. leprae is the second most prevalent mycobacterial species in humans 
(Wagner el al., 2004). M. leprae is the cause of leprosy, a chronic disease found in 
several developing countries, reaching an estimated global prevalence of 213,000 
cases (WHO, 2010). Traditionally humans were thought to be the only natural host 
for M. leprae; however, in 1975 nine-banded armadillo (Dasypus novemcinctus) 
were reported to harbor the disease (Walsh et al., 1975). M. leprae from human and 
armadillo cases in the Southern United States were subjected to comparative 
genomic analysis showing that the genome sequences of the predominant armadillo 
in that area and human strains shared a same unique genotype, suggesting a 
zoonotic character for the disease (Truman et al., 2010).  
In humans, leprosy elicits a range of cellular immune responses, clinically 
manifested as a demarcated lesion or multiple nodular lesions in the skin. It can also 
affect eyes and cause nerve damage (Britton et al., 2004). M. leprae is not cultivable 
in vitro, and the ―gold standard‖ diagnosis corresponds to a skin biopsy sample. 
Serological tests are challenging because of limited sensitivity and specificity. 
Results of PCR analysis can vary depending if the disease has a paucibacillary or 
multibacillary form, but together the histopathological analysis offer the best 
diagnosis approach (Scollard et al., 2006).  
 
1.2 Anti-tuberculosis therapy and drug resistance 
Following the WHO guidelines for TB therapy, newly detected cases of 
pulmonary TB should receive a regimen combining izoniacid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) during the first two months, followed by a 
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4-month treatment with INH and RIF (WHO, 2010). TB chemotherapy is affected by 
the slow-growing characteristics and the metabolic intracellular state of the bacilli 
(Blanchard et al., 1996). The mechanism of action varies between the drugs having 
different mycobacterial targets. INH is a prodrug that requires activation by the 
mycobacterial catalase peroxidase enzyme (KatG). INH is active in the growing state 
of the bacilli, inhibiting the synthesis of mycolic acids (Tripathi et al., 2005). RIF 
interferes with bacterial transcription by binding to the β-subunit of the RNA 
polymerase (Johnson et al., 2006) and can be active in bacilli with reduced 
metabolism or actively growing (Mitchison et al., 2000). EMB is a synthetic amino 
alcohol having as a site of action the biosynthesis of arabinan present in 
arabinogalactan and lipoarabinomannan (Tripathi et al., 2005). Finally, PZA is a 
structural analog of nicotinamide and is more effective in non-replicating tubercle 
bacilli compared to metabolically active bacilli (Zhang et al., 2002). The mechanism 
of action of PZA has been proposed to be through acidification of the bacterial 
cytoplasm and de-energization of the membrane (Zhang et al., 2005). However, a 
recent study also demonstrated that PZA inhibited translation by targeting ribosomal 
proteins (Shi et al., 2011). 
In 1994, WHO initiated the global project on anti-TB drug-resistance 
surveillance. Currently, there is an estimated of 650,000 cases of multidrug-
resistance (MDR)-TB among the worldwide TB prevalent cases (WHO, 2011). As 
part of the DOTS strategy, patients have a supervised treatment and monthly 
sputum samples are collected until having two consecutive negative results for the 
smear examination (Johnson et al., 2006). TB drug resistance dates back to the 
1950s and 1960s. At that time, treatment was characterized by the use of a 
monotherapy either with streptomycin, INH or PZA. This drug regimen was followed 
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by a rapid development of bacterial resistance, leading to the use of a combination 
therapy (Hall et al., 2009).  
Combination therapy and the introduction of RIF by the end of the 1960s 
produced a decrease in drug resistance in developed monitored countries. However, 
during the 1980s, the establishment of HIV-acquired immune deficiency syndrome 
(AIDS) impacted the increase of TB transmission and outbreaks of MDR-TB resistant 
to INH and RIF (Johnson et al., 2006). Moreover, the situation was worsened by the 
emergence of extensively drug-resistant (XDR)-TB, defined as TB with resistance to 
at least INH, RIF, any fluoroquinolone (FQ) and one of three second-line injectable 
drugs (amikacin, kanamycin or capreomycin) (Banerjee et al., 2008). 
Drug susceptibility of Mtb can be determined at the molecular level, detecting 
mutations in the genes involved in the drug mechanism or by inhibition of the 
bacteria growing in a medium with the antituberculous drug (Kim, 2005). 
 
 1.3 Pathogenesis of Tuberculosis  
Mtb enters the respiratory route contained in aerosol droplets and reaches the 
alveoli. The bacilli are then disseminated by the lymphatic circulation to regional 
lymph nodes in the lung, forming the primary or Ghon complex (Smith, 2003). 
Macrophages and dendritic cells play a pivotal role during the immune response. 
The bacteria contact tissue dendritic cells that are activated and migrate to the 
draining lymph node, stimulating naïve T cells (Saunders et al., 2000). CD4+ and 
CD8+ T cells that participate in the activation of Mtb infected macrophages through 
cytokines such as gamma interferon (IFN-γ) and lysis via apoptosis and cytotoxic T 




The bacteria also contact resident macrophages of the respiratory tract 
through mannose and/or complement receptors, leading to the phagocytosis process 
and the formation of an endocytic vacuole called the phagosome. The normal 
phagosomal maturation implies phagosome-lysosome fusion, providing a hostile 
environment for the bacteria, including acid pH, reactive oxygen intermediates, 
lysosomal enzymes, and toxic peptides. However, pathogenic mycobacteria can 
subvert this, by inhibiting the phagosome-lysosome fusion (Smith, 2003). Lipids 
contained in the cell wall of mycobacteria, such as lipoarabinomannan and its 
precursor phosphatidylinositol mannoside, have been shown to be involved in the 
arrest of phagosome trafficking (Vergne et al., 2004). 
The formation of the granuloma is a characteristic histo-pathological feature of 
TB triggered by chemokines produced by infected macrophages at the infectious 
site, leading to the accumulation of macrophages, lymphocytes and dendritic cells 
(Peyron et al., 2008). Tumour necrosis factor (TNF)-α is the dominant cytokine 
responsible for chemokine production and subsequent cell recruitment. The 
downregulation of this proinflammatory response is linked to a cellular immune 
response mediated by IFN-γ (Russell, 2007).  
With the development of the cellular immunity, macrophages carrying the 
bacilli are killed, and result in a caseous center in the granuloma surrounded by a 
cellular zone of fibroblasts, lymphocytes and blood-derived monocytes. Despite the 
low pH, low oxygen and toxic fatty acids that characterize the caseous center, some 
bacilli remain dormant (Smith, 2003). In vitro studies showed that Mtb activates 
metabolic pathways for using fatty acids as the sole carbon source under anaerobic 
conditions (Flynn et al., 2001). Also oxygenated mycolic acids are one of the major 
compounds of the TB cell wall and are proposed to be crucial for the formation of 
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macrophages filled with lipid-containing bodies, called foamy macrophages (FM) 
where the bacilli can hide and persist inside the granuloma (Peyron et al., 2008). 
Bacteria have been also found associated with macrophages present in the 
peripheral leukocytic area of the granuloma, being positive for the expression of 
isocitrate lyase. This enzyme is important for the use of fatty acids as a carbon 
source and has been shown upregulated by Mtb in those inflammatory macrophages 
where there is a hostile environment and restricted access to nutrients (McKinney et 
al., 2000). 
The cellular immune response defines the future of the infection, leading to an 
arrest or progression of the disease., also referred as latent or active disease, 
respectively (Tufariello et al., 2003). The progress of the disease is characterized by 
a liquefactive necrosis and loss of the fibrous granuloma capsule integrity. Caseous 
material will be discharged into proximal blood vessels and airways, causing a 
systemic dissemination of the bacilli (Dheda et al., 2005). This state of the disease is 
highly infectious because of the large number of bacilli in aerosolized droplets and in 
sputum. Consequently, sputum is the primary clinical sample used for TB diagnosis 
(Wallis et al., 2001). 
Lymph nodes are the most common site for extrapulmonary TB, but 
eventually the disease can be disseminated to several locations in the organism 
(Sharma et al., 2004). The clinical manifestations of disseminated TB, also called 
military TB, are non-specific and can include fever, anorexia, weight loss and cough 





2. Mycobacterial cell wall and lipids compounds 
2.1 Mycobacterial cell wall 
Because of their cell wall structure, mycobacteria have long been considered 
Gram- positive; despite this, they also possess some features common to the Gram-
negative cell wall (Rastogi, 1991), including an outer membrane like structure 
(Zuber, 2008). Using the standard reference of bacterial phylogeny based on 16S 
ribosomal RNA sequence comparison, Mtb belongs to the high G+C Gram-positive 
bacteria. However, measuring the distance between ancestral units in the genome 
tree, Fu et al. (2002) showed that the evolutionary distance from Mtb to the nearest 
ancestor of Gram-positive bacteria is 16.0% and to the nearest ancestor of Gram-
negative bacteria is 5.4%. The acid-fastness of the cell wall has been attributed to 
several cell wall compounds, including outer lipids, mycolic acids bound to the 
arabinogalactan fraction and free hydroxyl and carboxylate groups of cell wall lipids. 
This hydrophobic barrier allows phenol-based stains to penetrated and make it 
resistant to decolorization by acid-alcohol (Bhatt et al., 2007). 
The mycobacterial cell wall has an indisputable role in the success achieved 
by these pathogens. The high content of lipid in the cell envelope is responsible for 
the notable hydrophobicity and the consequent resistance to chemical injury and lytic 
enzyme attack from the host (Ratledge, 1982). They exhibit resistance to most 
common antibiotics and general chemotherapeutic agents; atypical mycobacteria are 
especially resistant (Brennan and Nikaido, 1995). Differences in permeability can 
exist between species, Mycobacterium chelonae, has a very low permeability 





Figure 1. Mycobacterial cell wall. The scheme shows some of the most relevant 
compounds in the plasma membrane, outer membrane and capsule. 
Arabinogalactan (AG), Arabinomannan (AM), diacyl threhalose (DAT), glucan (GLU), 
lipoarabinomannan (LAM) lipomannan (LM), pentaacyl trehalose (PAT), 
dimycocerosates of the phthiocerol family (PDIMs), peptidoglycan (PG), phosphatidyl 
inositol manosside (PIMs), sulfolipid (SL). (Adapted from Chatterjee et al., 1998 and 
Minnikin et al., 2002; copyright permission obtained). 
 
The general architecture of the Mtb cellular envelope (Figure 1) is a plasma 
membrane surrounded by a covalently linked mycolic acid, arabinogalactan and 




























structure with lipids that are present on the surface of the cell envelope. A 
polysaccharide-rich capsule like material has also been described (Daffé, 1999; 
Crick et al., 2001).  
 
The plasma membrane of the mycobacterial cell has a basic conformation 
that does not differ from other plasma biological membranes. It is structured of polar 
lipids with hydrophilic head groups and fatty acid chains, combining a mixture of 
straight chain, unsaturated and mono methyl branched fatty acid residues with less 
than 20 carbons. The main fatty acids isolated from the plasma membrane are 
palmitic (C 16:0), octadecenoic (C 18:1) and 10-methyl octadecanoic (or 
tuberculoestearic) (Daffé, 2008). The common amphipatic polar phospholipids of 
mycobacteria are diphosphatidylglycerol, phosphatidylethanolamine (PE), and 
phosphatidylinositol (PI). Menaquinones and carotenoids are also present, having a 
role in the respiratory system of membranes and as protective agents against 
photodynamic damage, respectively (Minninkin, 1982).  
The peptidoglycan of the cell wall core of Mtb consists of N-acetylglucosamine 
(GlcNAc) and modified muramic acid residues. Muramic acid is modified to N- acetyl 
muramic acid as in the peptidoglycan of other bacteria, but it is also oxidized to N-
glycolyl and substituted with tetrapeptide (L-alanyl-D-isoglutaminyl-meso-
diaminopimelyl-D-alanine) chains. Finally, cross-linking can occur between two 
meso-diaminopimelic acid (DAP) residues or between DAP and D-alanine residues 
(Crick et al., 2001). 
The arabinogalactan (AG) that is covalently attached to the 6 carbon of the N-
acetyl or N-glycoly-muramic acid of peptidoglycan and has a branched structure 
consisting mainly of 1  5 linked D-arabinofuranose units and 1  4 linked D- 
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galactopyranose units, in an approximate ratio of 5 to 2. Some of the arabinose units 
also form non-reducing terminal ends (Lederer et al., 1975). AG is esterified with 
mycolic acids and it has been proposed that the non-mycolated motifs work as 
epitopes for interaction with the immune system, which could explain the antigenicity 
of the arabinan component (Mc Neil et al., 1991).  
Minnikin (1982, 1991) originally proposed a double layer model for the outer 
membrane (OM), in which the mycolic acids are, in part, covalently linked to the cell 
wall arabinogalactan and form the inner leaflet of the asymmetrical bilayer. The 
outermost leaflet is proposed to be composed of various glycolipids, and of species-
specific lipids such as glycopeptidolipids, phthiocerol dimycocerosate, and sulfolipids 
(Minnikin 1982., Rastogi, 1984). 
Mycolic acids (MAs) in mycobacteria exist in the cell in two basic forms. The 
major portion is covalently bound to the cell wall, esterified to the 5-hydroxy groups 
of arabinofuranosyl residues to form the terminal [5-mycoloyl-β-Araf- (12)-5-
mycoloyl-α- Araf-(1)] units of AG. MAs are also found loosely associated with the 
cell wall, esterifying a variety of carbohydrate containing molecules like glucose, 
trehalose or polyprenylphosphomannose (Mc Neil et al., 1991)). Mtb can also 
release the MAs as free fatty acids (Ojha et al., 2008) 
The capsule structure is the most external component of the mycobacterial 
cell, and its true existence and structure has been controversial. The putative 
capsule is not covalently attached to the cell wall (Daffé et al., 1999). 
Polysaccharides and proteins are the main components and it only contains 1 to 6 % 
of lipids. A 120 kDa glycogen-type glucan, a 13 kDa arabinomannan and a 4 kDa 
mannan have been identified as the major capsular polysaccharides (Ortalo-Magné 
et al., 1995). Phospholipids such as phosphatidylinositol mannosides and 
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phosphatidylethanolamine (PE), commonly found in the plasma membrane, were 
also observed as part of the capsular material (Ortalo-Magné et al., 1996). The -
glucanes founded in the capsular region have been proposed to play a role in the 
host immune response. Gagliardi et al., (2007), showed that -glucane is capable to 
interfering with class I CD1 molecule expression, a family of major histocompatibility 
complex (MHC)-class-I-like glycoproteins that present unique lipids found in Mtb to 
activate diverse T cells (Barral et al., 2007). They are also associated with 
interference of monocyte differentiation to dendritic cells (Gagliardi et al., 2007). The 
capsule composition and thickness differ between different species of mycobacteria 
and influence the interaction with macrophages. Saprophytic and opportunistic 
pathogenic mycobacteria are more readily ingested than are members of the Mtb 
family which exhibit a thicker capsule (Stokes, 2004).  
 
2.2 The lipids compounds of the mycobacterial cell wall 
2.2.1 Mycolic acids 
MAs are very abundant in the mycobacterial cell wall. They comprised about 
34% of the weight in M. microti and they are considered as a hallmark of the 
Mycobacterium genus (Davidson, 1982). MAs have been extensively used for 
taxonomic purposes and can be distinguished from other MAs containing genera, 
including Corynebacterium (C20 to C38), Rhodococcus (C34 to C52) and Nocardia (C40 
to C60) according to the longer length of their carbon chain (Butler el al, 2001). 
The basic structure of MAs (Figure 2) is comprised of a -hydroxy-alkyl 
branched unit. The meromycolate moiety is up to C56 in length and the saturated -
branch has a length of C20 to C24. In the meromycolate chain there are positions that 
can be occupied by double bonds, cyclopropane rings or polar modifications that 
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contain oxygen functions and that tend to be at the distal position (Barry et al., 1998).  
Regarding this, the least polar MAs without oxygen functional groups are termed -
mycolates and the more polar MAs possess an oxygen function that can be a keto-, 
a methoxy- or a hydroxyl-group in slowing growers and an epoxy ring in rapid-
growing species. In some mycobacterial species the keto-mycolic acids can be 
oxidized yielding a wax ester (Rafidinaviro et al., 2009) 
Non-polar modifications occur at the distal and the proximal positions and 
include cis or trans double bonds and cis or trans cyclopropanes (Barry et al., 1998). 
In Mtb, -MAs have two cyclopropane rings, mostly present in the cis configuration 
and the keto- and methoxy-MAs have one cyclopropane that can be in cis or trans 
configuration (Watanabe et al., 2001). 
 
 
                        
 
Figure 2. MA structure and mycolate classes in Mtb. (Takayama et al., 2005; 





The saturated structure of the -branch (typically 24 carbon) and the length of 
the meromycolic chain (almost 60 carbon) may be influencing the regular parallel 
packing of their hydrocarbon chain, as well as the oxygen functions with cis double 
bonds and cis cyclopropane structures by producing kinks in the chains (Brennan 
and Nikkaido, 1995). 
Cis-cyclopropanation of the -MAs was found to be critical for the activation of 
the innate immune responses during early infection (Rao et al., 2005). In contrast, 
trans-cyclopropanation in Mtb has shown to limit the virulence by suppressing 
inflammatory response during infection, implying a mechanism for bacterial 
persistence (Rao et al., 2006). Cyclopropanation of the meromycolate chain is also 
related to other potential virulence determinants. Mycobacterium smegmatis does 
not modify its mycolates with cyclopropanation. However, when M. smegmatis was 
genetically modified such that it converted its distal cis double bond to a cis 
cyclopropane ring there was enhanced protection of the cell to oxidative stress 
(Yuan et al., 1995).  
-mycolates (C74-82) are the most widespread and have been found in every 
mycobacterial species examined, followed by ketomycolates. The -1 methoxy-
mycolates are the most restricted, occurring in some fast growing strains (Kremer 
and Besra, 2005). ‘-mycolates have a shorter carbon chain (C60–68) than -
mycolates and have been observed in various rapid growers such as M. smegmatis, 
M. chelonae, and M. parafortuitum (Kaneda et al., 1986). Methoxy- mycolates, with 
few exceptions, appear to be only present in pathogenic mycobacteria and slow 
growers (Barry el al, 1998). Evidence suggests the ability of slow-growing 
pathogenic mycobacteria, to modify their mycolate profile depending on the 
environmental conditions. Ketomycolate production from the Mtb H37Rv strain 
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appears to be increased during exponential growth and bacteria growing within 
macrophages (Yuan et al., 1998). 
The role of the different mycolate classes was addressed by Vander Beken et 
al. (2011). Synthetic MAs of the major classes, α-, keto- and methoxy-mycolate that 
varied in cis versus trans cyclopropane configuration were studied for their ability to 
elicit a pulmonary inflammatory response. Whereas the non-oxygenated α-MAs did 
not exert a response, the oxygenated keto- and methoxy MAs with a cis-
cyclopropane configuration showed an inflammatory response that was stronger in 
the methoxy-MA class. This situation was different in the trans orientation where the 
keto-MAs showed an anti-inflammatory activity and methoxy-MAs diminished their 
inflammatory role. The origin and biological function of free MAs have been studied 
by Ojha et al. (2008, 2010). Free MAs were shown to be present in biofilms formed 
in Mtb cultures and further studies in M. smegmatis linked the presence of free MAs 
with the trehalose dimycolate (TDM) hydrolysis produced by a serine 
carboxyesterase. 
MAs can be presented to T cells by the CD1 family of MHC-like molecules 
(Beckman et al., 1994). Montamat-sicotte et al. (2011) showed MAs as one of the 
major targets during active TB, showing a T cell response similar to that obtained 
with immunoprotein antigens such as ESAT-6 and CFP10. The IFN-γ response 
triggered by MAs inserted into liposomes as a tracheal treatment, prevented the 
airway inflammation of sensitized mice used as an asthma model, supporting the 




2.2.2  Phosphatidylinositol based glycolipids 
Another molecule that has a major presence in the mycobacterial cell 
envelope is the lipoglycan lipoarabinomannan (LAM). LAM and the LAM precursor 
lipomannan (LM) are anchored to the plasma membrane by a phosphatidylinositol 
mannoside (PIM), commonly PIM2. The mannan core is based on an α1→6 linked 
backbone branched by single mannopyranosyl residues, followed by a D-arabinan 
domain in the case of LAM. The predominant fatty acyl chains are palmitate (C16:0) 
and 10-methyloctadecanoate (tuberculostearate, C19) (Chatterjee, 1998).   
The non-reducing terminus of the arabinan of LAM can be uncapped 
(AraLAM) or either capped with mannose (ManLAM) or inositol phosphate (PILAM). 
The differences between the AraLAM and ManLAM motifs were proposed as an 
indicator between virulent and avirulent strains, respectively (Chatterjee et al, 1992). 
However, the avirulent Mycobacterium bovis Bacille Calmette Guerin (BCG) strain 
and the virulent Mtb H37Rv strain were found to belong to the ManLAM class 
(Venisse et al., 1993). PILAMs has been isolated from rapidly growing mycobacteria 
such as M. smegmatis (Khoo et al., 1995) and are characterized as proinflammatory 
molecules, stimulating the production of TNF-α and IL-12, while ManLAMs play an 
anti-inflammatory role, inhibiting the human macrophages/dendritic function for their 
production (Vercellone et al., 1998). These facts are in agreement with the capacity 
of Mtb and M. bovis BCG to survive and multiply inside macrophages (Nigou et al., 
2002). Evidence has been provided about the role of LAM during the immune 
response. LAM induces a physical association between the signaling domains of 
Toll-like receptor (TLR) 1 and TLR2.  TLR1 and TLR2 are pivotal components of the 
mammalian innate immune response and would mediate the mechanism for LAM-
induced cellular activation (Tapping et al., 2003), and cytokine production. The 
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induction by LAM of TNF-  release could explain some of the characteristics of TB, 
such as fever, weight loss, and necrosis (Moreno et al., 1989). ManLAM triggers a 
preferential induction of interleukin (IL)-10 that is going to negatively regulate the 
caspase and prevents the Mtb-induced calcium influx. These events are responsible 
for the inhibition of apoptosis in Mtb-infected macrophages (Nigou et al., 2002). 
As mentioned, PIMs play a role as the common anchor for LM and LAM, but 
they can also exist as free glycolipids in the plasma membrane or in the cell wall. 
They are synthesized by all species of mycobacteria and the predominant forms are 
mono- and diacylated PIM2 and PIM6. PIMs activate human and murine natural killer 
(NK) T cells via CD1d, triggering antigen-specific IFN-  production and cell-mediated 
cytotoxicity in a CD1d-restricted way (Fischer et al., 2004). PIM6 and PIM2 activate 
primary macrophages to secrete TNF-  via TLR-2 activation, contributing to the 
innate immunity necessary to contain latent infection (Gilleron et al., 2003). 
 
2.2.3 Glycolipids based on trehalose 
Another important group of lipids in the Mtb cell wall structure are the acylated 
trehaloses. The cord factor, trehalose 6, 6‘- dimycolate (TDM), consists of one 
trehalose attached to two MAs moieties (Noll et al., 1956). Hunter et al. (2006) 
discovered that depending on its conformation, TDM has two sets of biological 
activities. In aqueous suspension it has a micellar conformation, where the surface 
consists in trehalose moieties with no exposed fatty acids. This form is non-toxic and 
protects organisms from killing by macrophages, preventing phagosome/lysosome 
fusion and acidification. Conversely, in a monolayer conformation becomes highly 




The molecular structure of TDM, exhibits differences according the 
mycobacterial species and subspecies (Fujita et al., 2005). TDM can induce 
granuloma formation   associated with neovascularization through cytokine-
dependent mechanisms (Saita et al., 2000). This lipid also modulates critical 
immunological mediators like cytokines and nitric oxide (Lima et al., 2001) and 
provides striking resistance to desiccation of membranes (Harland et al., 2008). TDM 
affects the integrity of the mitochondrial membrane system, inhibiting the oxidative 
phosphorylation process (Kato, 1970). Despite all these properties, TDM has also 
been found in non-pathogenic mycobacterial species (Mompon et al., 1978). It has 
been proposed that the cyclopropane modification of TDM is necessary for the 
cording morphology, associated with virulence. The avirulence of saprophytic 
mycobacteria would be explained by the absence of TDM with cyclopropanation of 
MAs (Glickman et al., 2000). 
  Other members of the trehalose containing glycolipids group are made of an 
- ‘-D-trehalose esterified with up to five multiple methyl-branched long-chain fatty 
acids and are characteristic of the envelope of pathogenic mycobacteria. The 
trehalose esters are comprised of sulpholipids (SL), diacyltrehaloses (DAT), 
triacyltrehaloses (TAT) and polyacyltrehaloses (PAT) (Rousseau et al., 2003). Their 
role in serodiagnostic studies has been evaluated by comparing the antigenicity 
between SL, DAT, TAT and TDM. SL-I showed the best sensitivity and specificity for 
IgG and IgA responses (Julián, et al., 2002).  
 
2.2.3.1 Sulfolipids 
Sulfolipids (SL) are trehalose derivatives acylated with two to four fatty acids. 
The sulphate ester is at position 2 of trehalose, a straight-chain fatty acid (palmitic or 
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stearic acid) is found at position 2‘ and one to three hepta- or octa-methyl-branched 
phthioceranic and hydroxy-phthioceranic (C31-C46) acids are found in the 3‘, 6 and 6‘ 
positions (Neyrolles et al., 2011). Sulfatides have been only isolated from Mtb and M. 
canetti, but not from other members of the MTBC (Neyrolles et al., 2011). Studies 
performed by Goren et al. (1976) using chromatographic separation and mass 
spectrometry, described SL-I as the principal sulfatide in Mtb. However, in a recently 
study of Mtb H37Rv, employing high-resolution multiple-stage linear ion-trap mass 
spectrometry with electrospray ionization, SL-II was described as the major class 
(Rhoades et al., 2011). 
Between the biological activities of purified SL, the most controversial is their 
ability to prevent phagosome lysosome fusion in murine macrophages (Goren et al., 
1976). Other biological activities associated with SL-I are strong inhibition of the 
respiration and phosphorylation in the mitochondria, and disruption of the 
mitochondrial membranes (Kato et al., 1974). The generation of mycobacterial 
mutants has contributed to deciphering the role of these compounds. Pks2 gene 
mutants are incapable of producing major acyl constituents of SL such as 
hydroxyphthioceranic acids and hepta and octamethyl phthioceranic acids (Sirakova 
et al., 2001). The SL deficiency of a pks2 mutant of Mtb H37Rv did not contribute 
significantly to the virulence of the Mtb strain (Rousseau et al., 2003). Other in vivo 
studies showed no toxic effects with the use of high doses of SL-I in mice; however, 
a synergistic activity with the toxicity of cord factor was achieved when the two lipids 
were injected simultaneously into mice (Kato et al., 1974).  
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2.2.3.2 Other acylated threhalose molecules 
The fatty acyl substituents of trehalose can be of three types: i) trehaloses 
acylated with mycolipenic acids (C16-C19), ii) acylated with mycolipanolic acid (C24-
C28), and iii) acylated with mycosanoic acids (C21-C25) (Besra et al., 1992).  
Mycolipenic acids (phthienoic acids) are the major acyl substituents found in the 
trehalose containing glycolipids PAT, TAT and some forms of DAT, and they are 
easily detected using simple gas-liquid chromatography. They have been isolated 
only from the TB complex, specifically Mtb, M. bovis and M. africanum but not 
detected in the avirulent Mtb H37Ra or in the attenuated vaccine strain M. bovis 
BCG (Daffé et al., 1988). These fatty acids are noted as potent inhibitors of 
leucocyte migration in vitro (Husseini and Elberg, 1952).  
Dubey et al. (2002) achieved the inhibition of mycolipanoic and mycolipenic 
(phthienoic) acids synthesis by disrupting the mycocerosic acid synthase like gene 
(msl3). As a consequence of this mutation, the growth pattern and morphology 
changed, and the cells appeared to stick to each other. This situation could be 
explained by the absence of the acylated trehaloses producing an exposure of 
hydrophobic surfaces of components like dimycocerosyl phthiocerol. The wild type 
H37Rv strain and the msl3 mutants were compared by the study of mouse bone 
marrow macrophages. The mutant strains showed a higher entry rate into host cells 
as compared to the wild type strain, but not significant differences in the persistence 
and replication. It was concluded that deficiencies in DAT and PAT produced by 
msl3 mutants, modified the surface properties of the bacteria, however other 
amphilic molecules, such as SL, can ensure the attachment of the capsule to the 
host cell (Rousseau et al., 2003). 
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2.2.4 Phenol glycolipids 
Phenol glycolipids (PGLs), also called mycosides, are present in some 
mycobacterial strains and possess mycocerosic acids (C27-C34), esterified to a 
phenolphthiocerol glycosylated with an oligosaccharide (Minnikin, 1982). PGLs are 
known to be produced by M. leprae (PGL-1), M. kansasii (mycoside A), M. bovis 
(mycoside B), a few strains of Mtb (PGL-tb) and a few of other slow-growing 
mycobacteria such as M. marinum, M. gastri, M. ulcerans, M. microti and M. 
haemophilum (Guilhot et al., 2008).  
In the case of M. leprae, PGL-1 has been vinculated to the binding of 
Schwann cells, affecting the function of the peripheral nervous system (Ng et al., 
2000). Generally, clinical isolates of Mtb lack PGL production due a mutation in a 
polyketide synthase gene (pks1-15) (Constant et al., 2002). The exception is the W-
Beijing family of Mtb that possesses an intact pks1-15 (Reed et al., 2007). Beijing 
strains stimulate weaker production of TNF-  and IL-12 when infecting human 
monocytes. Despite this, PGL-tb is not considered a dominant suppressor factor for 
the cytokine response, but is proposed to be part of an orchestrated response for the 
particular strain (Sinsimer et al., 2008).  
 
2.2.5 Mycobacterial waxes 
The mycobacterial waxes present in the cell wall are complex lipids with a 
high molecular weight. The phthiocerol dimycocerosates (PDIMs) are composed of a 
long -diol chain diesterified with methyl-branched long chain mycocerosic acids 
(Minnikin et al., 1985). PDIMs have been found in Mtb, M. bovis, M. gastri, M. 
haemophilum, M. kansasii, M. leprae, M. marinum and M. ulcerans (Minnikin et al., 
2002), and were found to be a virulence factor in mice (Cox et al., 1999). These 
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lipids interact with the host during the phagocytosis of Mtb, by inducing changes in 
the lipid ordering of the plasma membrane and the prevention of phagosomal 
acidification (Astarie-Dequeker et al., 2009). In Mtb, insertional mutants unable to 
synthesize or translocate PDIMs exhibit higher cell wall permeability and are more 




















3. Diagnosis of tuberculosis 
3.1 Introduction 
An early diagnosis of the individuals with active TB, leads to an effective 
therapy, reducing the transmission rate (Menzies et al., 2011). A definitive case of 
TB can be diagnosed from a clinical specimen by culture or by non-conventional 
techniques such as a molecular line probe assay (Goto et al., 1991). Several 
biomarkers are used for TB diagnosis, in the area of clinical trials, a biomarker is 
defined as a characteristic feature that is objectively measured and evaluated as an 
indicator of a normal or a pathological process, or the response to an intervention 
(Biomarkers Definitions Working Group, 2001). 
In countries that lack enough resources and laboratory capacity, the smear 
examination is fundamental, and diagnosis of TB can be done through one or more 
sputum smear examinations positive for acid-fast bacilli (AFB) (WHO, 2010). 
Conventional light microscopy is routinely used, but it is noted for low sensitivity, 
because of the need for more than 104 bacilli per ml of sputum. Thus, half or more of 
the cases of active pulmonary TB are misclassified as smear-negative (Chan et al., 
2000). To strengthen the technique, fluorescence smear microscopy has been 
introduced, using an acid-fast fluorochrome dye (eg, auramine O or auramine-
rhodamine) and a halogen or high-pressure mercury vapour lamp as a light source. 
The technique has shown to be more sensitive than conventional microscopy, and 
has similar specificity. It also has the advantage of using a lower power objective 
lens compared to a light microscopy, allowing the microscopist to cover the same 
area of the slide in less time (Steingart et al., 2006). 
Culture remains as the gold standard for diagnosis of TB and is about 100 
times more sensitive than the smear microscopy applied to sputum samples (Aryan 
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et al., 2010). The main limitation to culture is the long period of incubation (4 to 8 
weeks), also called turn around time (TAT) (WHO, 2007). An improvement was 
achieved with the use of semi-automated commercial liquid systems that can reduce 
the TAT to 10 days. BACTEC 460 and BACTEC MGIT 960 (Becton Dickinson) are 
examples of these liquid systems. The BACTEC 460 uses 14C-labelled fatty acid as 
a substrate to measures Mtb growth based on the amount of 14CO2 released. The 
MGIT system does not require a radioactive substance and is a fully automated 
system that detects the amount of oxygen consumption of growing microorganisms 
by the use of a fluorescence quenching-based oxygen sensor (Pheiffer et al., 2008). 
Another diagnostic tool that reflects the presence of viable Mtb is the use of 
mycobacteriophages. FASTplaqueTB assay (BIOTEC laboratories) utilizes a 
mycobacteriophage to target the mycobacterial cells. The use of a virucidal agent 
eliminates the bacteriophages that have not infected a target and only the 
bacteriophage progeny is amplified in sensor cellsTM (a rapidly growing 
mycobacterial strain, susceptible to the phage). The presence of plaques in the Petri 
dish is evidence of viable TB in the original sample (Marei et al., 2003). 
Despite these improvements, culture tests are technically demanding and 
time-consuming. Chest radiography is also used, but it lacks of specificity especially 
in those immunocompromised individuals, because of the atypical x-ray patterns 
(McNerney et al., 2011). Therefore, there is a need of other methods to subvert the 
weakness of the conventional tools applied in TB diagnosis (Aryan et al., 2010). 
 
3.2 An overview of the use of biomarkers in TB diagnosis 
The use of biomarkers in TB includes their application for immunologic 
responses detection, transcriptomics and proteomics of differentially expressed 
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genes and proteins, and metabolomics. Any combination of these has been 
proposed or studied as a tool to distinguish latent TB from active disease, predict risk 
of disease progression or portray the status of the infection (Parida, 2010). The use 
of biomarkers is also promoted as an alternative prognostic tool for the 
establishment of an adequate prophylactic chemotherapy, given the high percentage 
of worldwide TB infected population and the subsequent risk to progress to an active 
disease after an immune system weakness (Kaufmann et al., 2008). 
Moreover, biomarkers can be used as surrogate endpoints in vaccine 
development. In this case biomarkers intend to substitute a clinical endpoint, 
predicting clinical outcome in terms of benefit, or harm, or lack of benefit or harm 
(Biomarkers Definitions Working Group, 2001). In this scenario, biomarkers could 
help to accelerate the development process at different stages of clinical trials 
(Kaufmann et al., 2008). Because of the biological complexity of most infections, the 
use of a set of biomarkers increases the possibility of an accurate diagnostic. In the 
case of TB, the detection of circulating biomarkers that are secreted by the pathogen 
has the advantage of being detected in samples such as blood, urine or sputum, 
avoiding invasive procedures such as cerebrospinal fluid, lymph node aspirate or 
other biopsies and can be especially useful in patients with advanced humoral 
immunosuppression (Mc Nerney et al., 2011).  
 
3.2.1 DNA/RNA biomarkers in TB 
Nucleic acid amplification (NAA) tests are used to amplify targeted nucleic 
acid regions of the Mtb complex and they can be applied directly to clinical 
specimens, such as sputum. Thus they are also called ―direct amplification tests‖ and 
are present as commercial kits or in-house assays (Nahid et al., 2006). The main 
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advantage of NAA is reducing the TAT to one day. The Gen-Probe Amplified 
Mycobacterium tuberculosis Direct (MTD) test (Gen-Probe Incorporated, San Diego, 
CA) employs a single-stranded labeled DNA probe, complementary to the rRNA of 
the pathogen (Teo et al., 2011). Xpert MTB/RIF (Cepheid, Sunnyvale, CA) is a 
recommended test by the WHO that can be used directly on sputum samples and is 
an automated molecular test for Mtb and RIF resistance detection. A hemi-nested 
real-time polymerase-chain-reaction (PCR) assay is used to amplify a Mtb-specific 
sequence of the rpoB gene (involved in the coding of the β subunit of the RNA 
polymerase) that is probed with molecular beacons for mutations within the RIF-
resistance region (Boehme et al., 2011). Another NAA test is the loop-mediated 
isothermal amplification (LAMP) where high amounts of insoluble salt of magnesium 
pyrophosphate are produced in the amplification reaction, allowing a visual naked-
eye detection of positive reactions by changes in turbidity. LAMP has been used to 
target the insertion sequence (IS) 6110 and the genes rrs and gyrB of Mtb. This 
diagnostic tool has been used for the detection of Mtb in sputum samples. The 
advantages of this technique include its lower cost and rapidity when compared to 
the IS6110 targeted by classical PCR, and it also does not require a thermal cycler 
because reactions are performed at a fixed temperature (60–65 C) (Aryan et al., 
2010).  
Other biomarkers from host origin include the DNA fragments of Mtb, termed 
transrenal DNA (tr-DNA). Tr-DNA have been detected in the urine of patients 
infected with pulmonary TB, suggesting the possibility that Mtb DNA could be 
cleared through the kidneys after an apoptotic process of the infected cells (Cannas 
et al., 2008). The use of PCR followed by amplicon characterization using 
electrospray ionization mass spectroscopy has been used for Mtb genotyping, and 
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NTM and MDR characterization (Massire et al., 2010). By the use of softwares the 
organism can be identified by the measure of the mass-to-charge ratio of the 
amplicon and also the base composition (Wolk et al., 2009). 
 
3.2.2 Immunological biomarkers 
Biomarkers involved in the immunological response have been used for the 
study of TB in active and non-active individuals, and also in the evaluation of 
antituberculosis therapy. The MycoDot™assay is based on the detection of LAM 
antibodies using an immuno-dot-blot technique. Because this technique is developed 
on solid membranes supports, it has the advantages of being fast and does not 
require special equipment. Thus, it was suggested as a platform to use in rural or 
undeveloped areas with limited resources (Antunes et al., 2002). LAM has been 
explored in a number of studies using serum, urine, sputum and cerebrospinal fluid 
(CSF). Studies in unprocessed urine, provides a tool for the diagnosis of pulmonary, 
as well as extrapulmonary mycobacterial infection, using a direct antigen enzyme-
linked immunosorbent assay (ELISA) for LAM detection. LAM has been proposed to 
be released from metabolically active or degrading bacterial cells. Once in the 
bloodstream, LAM can be filtered by the kidneys, and detected (Boehme et al., 
2005). Clearview-TB® is a LAM antigen-detection ELISA, standardized for urine 
samples. Using this test, Dheda et al. (2010) determined the diagnostic accuracy of 
LAM in urine and sputum samples from HIV-infected patients belonging to different 
CD4 T cell categories. Results showed a promising use of this diagnostic tool, but 
limited to the group of HIV infected patients with smear negative and a CD4 count 
less than 200 cells/mm3. Sputum-LAM showed good sensitivity (86%) but poor 
specificity (15%) probably due to cross-reactivity with LAM-like microbial 
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carbohydrate surface molecules in the cell walls of mouth-residing organisms such 
as Candida, and many species of Actinobacteria. Clearview-TB ® was also used as 
a diagnostic for tuberculous meningitis (TBM) using CSF samples. The results also 
suggested this assay as useful for TBM in HIV-infected individuals with advanced 
immunosuppression (Patel et al., 2010). 
Antigen 5 (38 kDa antigen), A60 antigen (a thermostable component of PPD), 
30kDa antigen and cord factor are examples of other antigens used (Cole et al., 
1996., Lu et al., 1996., Mc Donough et al., 1992). The groups that would benefit from 
these serological diagnosis correspond to young children, the elderly, HIV-positive 
individuals, and patients with extrapulmonary TB. This is because the difficulty in 
obtaining sputum samples from these individuals and the lower incidence of AFB in 
respiratory samples. The serological assays have the issue of a low sensitivity in the 
negative smear/positive culture group. This is a main limitation since this group 
would receive significant benefit using these diagnostic techniques (Chan et al., 
2000). 
Monocytes/macrophages have been proposed to be the main source in 
humans of neopterin, classified as a biochemical marker of cell-mediated immunity, 
released into body fluids (Berdowska et al., 2001). Serum neopterin is shown to be 
higher in patients with active TB than in healthy control groups and has also been 
used as a biomarker to evaluate the response of antituberculosis therapy showing a 
steadily decrease from the baseline point to the end of antituberculous therapy 
(Turgut et al., 2006).  
The importance of identifying those latent tuberculosis infection (LTBI) cases 
lies in providing an adequate therapy that prevents development of active disease 
(Ziv et al., 2001). The available tests to identify LTBI include the in vivo tuberculin 
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skin test (TST) and the ex vivo IFN-  release assays (IGRAs), which can identify an 
adaptive immune response (Mack et al., 2009). The TST is one of the few tests that 
has been continuously in use for about 100 years in clinical medicine and consists in 
the use of a purified protein derivative (PPD) which measures a delayed-type 
hypersensitivity (DTH) response in the skin (Mack et al., 2009). Tuberculin PPD is a 
crude mixture of antigens shared by different mycobacteria, thus affecting the 
sensitivity of the test (Jasmer et al., 2002). When individuals sensitized by Mtb are 
exposed to mycobacterial antigens, T-cells release IFN-  in a response to those 
antigens and this cytokine can be detected using IGRAs as ex vivo enzyme-linked 
immunospot (ELISPOT) assay or by the whole blood ELISA (Mack et al., 2009). 
ESAT-6 (Andersen et al., 1995) and CPF-10 (Berthet et al., 1998) are two proteins 
coded by the genes contained in the region of deletion 1 (RD1) present in Mtb and 
M. bovis, but excluded from the avirulent BCG strain. The deletion of RD1 in BCG 
has been suggested as an original attenuating mutation of this strain (Mahairas et 
al., 1996).  The IFN-   based T cell response assay to ESAT-6 and CPF-10 has been 
shown to detect active and latent TB (Lalvani et al., 2001). The commercially 
available assay T SPOT-TB (Oxford Immunotec, Oxford, UK) was used by Meier et 
al. (2005) to compare the results between T SPOT-TB and TST in 45 patients with 
confirmed TB, indicating a sensitivity of 100% versus 89% respectively (p=0.056). As 
Mack et al. (2009) proposed in his review, individuals diagnosed as positive by TST 
or IGRAs have a higher risk to progress to active TB. However, a proportion of them 
will not develop the disease because their immune system is able to control the 
infection or simply because they are no longer infected with living bacteria. Thus 
positive individual would best indicate ‗‗lasting TB immune responses‘‘ but not 
necessarily true ‗‗latent TB infection‘‘. 
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Differences between contacts of TB patients, who later develop TB disease 
(progressors), versus contacts who remain healthy (non-progressors), were 
analyzed using different immunologic biomarkers. The major difference in the 
adaptive immune response was a significantly lower proportion of CD4+ T cells in 
progressors compared to non-progressors. This was related with the concomitant 
decrease of the of the antiapoptotic gene Bcl2 leading to T cells apoptosis, a 
detrimental situation in the control of disease progression. Higher levels of IL-18, a 
precursor of IFN-γ production, were also founded in progressors pointing to have a 
role in the early stages of Mtb infections (Sutherland et al., 2011). 
 
3.2.3 Biomarkers identified by the use of proteomics 
Serum proteomic profiles from patients with active TB and controls were 
analyzed by surface-enhanced laser desorption ionization time of flight mass 
spectrometry. Amyloid A and transthyretin were identified as biomarkers associated 
with the inflammatory state of TB and the transport of retinoic acid, which stimulates 
monocyte differentiation respectively (Agranoff et al., 2006). Proteomics has also 
been explored in the biomarker field in the study of M. bovis and M. paratuberculosis 
in cattle. Sera protein profiles of experimentally infected animal either with M. bovis 
or M. paratuberculosis were compared, identifying common and distinct biomarkers 
for both diseases. A common biomarker was vitamin D binding protein precursor 
(DBP), known to be involved in macrophage activation and vitamin D transportation 
(Kisker et al., 2003). In the particular case of M. paratuberculosis, cathelicidins (a 
group of antimicrobial peptides) were identified at greater levels when 10 month post 




3.2.4 Metabolites as biomarkers for TB 
Metabolomics allow the study of all detectable metabolites of bacterium or 
host origin in a small number of experiments. TB can be detected by the analysis of 
very small metabolites including volatile compounds (VOCs). Surprisingly 
Hippocrates, an ancient Greek physician, recorded as one of the first test for TB the 
placing of sputum samples on hot coals, assessing the foul odour that was given off 
(Mc Nerney et al., 2011). In the same context, African giant pouched rats 
(Cricetomys gambianus) were trained for the diagnosis of TB in human sputum. 
Within the advantages of this method, the authors mentioned the resistance of the 
sniffers rats to TB infection and the larger amount of samples able to be screened. In 
this study the average daily ranging for sensitivities was from 72% to 100%, and the 
false-positives ranging was from 0.7% to 8.1% (Weetjens, 2009). 
Species-specific volatile metabolites from Mtb and M. bovis cultures grown in 
vitro were identified using gas chromatography/mass spectrometry. Four compounds 
corresponded to methyl phenylacetate, methyl p-anisate, methyl nicotinate and o-
phenylanisole, were detectable before the visual appearance of colonies. From the 
characterized compounds, methyl nicotinate was selected for validation in vivo. 
Nicotinic acid has an important role in oxidation-reduction reactions in mycobacterial 
metabolism. Higher levels of methyl nicotinate were shown in the smear positive 
samples from TB patients, compared with the control group (Syhre et al., 2009). 
In another study, VOCs in the breath of suspected TB patients and control 
individuals were analyzed by gas chromatography/mass spectroscopy and 
compared to VOCs produced by Mtb in vitro. A similar profile of VOCs was observed 
in breath and culture VOCs, and included naphthalene, 1-methyl- and cyclohexane, 
1,4-dimethyl- (Phillips et al., 2007). 
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4. TB lipids as biomarkers in Mtb 
4.1 Application of lipidomics for the study of Mycobacterium lipids as   
      biomarkers 
Because of the unique features of the TB cell wall, different cell wall 
compounds have been studied for their use as biomarkers. Through the use of 
lipidomics, lipid molecular species and their interacting moieties are characterized. 
Analytical methods, and in particular mass spectrometry (MS) and liquid 
chromatography (LC) have been used broadly in this research field (Wenk, 2005). 
Other techniques include in lipid research are thin layer chromatography 
(TLC), gas chromatography (GC) and high-performance liquid chromatography 
(HPLC). GC typically requires derivatization of the sample to make the analytes 
more volatile. Normal phase LC leads to separation of lipids on the basis of their 
class and reversed-phase chromatographic methods lead to retention time 
differences according to fatty-acyl composition. Initial separation of lipids by LC 
resolves compounds prior to enter into a mass spectrometer, resulting in less ion 
suppression, high ionization and enhancement of the sensitivity for minor molecular 
species (Wenk, 2005). 
A mass spectrometer measures the mass-to-charge ratio (m/z) of gas-phase 
ions. For electrospray (ES)-MS the sample is typically delivered to the mass 
spectrometer through a chromatographic device (e.g. column), afterwards it is 
ionized and vaporized in the ion source, and the resultant ions are sorted according 
to their m/z in the mass analyzer, providing a mass spectrum that displays the 
abundance and the m/z of the different ions (Griffiths et al., 2009). In addition to 
electron impact (EI) ionization and the soft ionization techniques electrospray 
ionization (ESI), matrix assisted laser desorption/ionization (MALDI) is also applied in 
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lipidomic studies. The choice of the ionization technique is going to depend of the 
chemical properties of the analyte. ESI is very efficient for the ionization of polar 
compounds and has the advantage of coupling the HPLC system to MS (Siuzdak, 
1994). For the analysis of less polar compounds atmospheric pressure chemical 
ionization (APCI) is more suitable. The main difference between these two 
techniques is that ions are generated in the liquid phase by using ESI and in the gas 
phase by using APCI (Schmitz and Benter, 2007).  
The mechanism of ion formation can vary. Analytes suitable for ESI analysis 
already possess charged groups such as quaternary amines, or can be charged by 
the gain or loss of protons. In the case of the positive ion mode, lipids tend to form 
positive ion adducts. Sodium adducts are the most common in crude lipids extracts 
from biological samples. Ammonium adducts can also be present when ammonium 
salt are used in the system. Fatty acids are typically observed deprotonated species 
detected in the negative ion mode (Cole, 2010). 
Mass spectral databases and software protocols for automated ion detection 
and identification; facilitate the differentiation of the mycobacterial lipid classes. 
―Mycomass‖, ―Mycomap‖ (Layre et al., 2011) and ―Mtb LipidDB‖ are examples. ―Mtb 
LipidDB‖ uses accurate mass measurements for lipid identification, providing 2,512 
lipid entities identified in negative or positive ionization mode, depending on their 
chemical structure (Sartain et al., 2011).  
Lipidomics have been applied for mycocerosic acids and tuberculoestearic 
acid (TSA) detection in sputum and CSF samples respectively. However, TSA 
detection has been questioned in specificity, because it is also present in other 
microorganisms of the Actinomycetales order (Alugupalli et al., 1998, Larsson et al., 
1987). Minnikin et al. (1993) tested the detection of TSA and mycocerosic acids by 
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GC and MAs by LC in sputum samples from TB patients. The integrated method 
showed characteristic profiles for each lipid category, supporting the idea that the 
use of a set of lipid biomarkers can help to subvert the lack of specificity. 
Mycocerosic acids have been also used as biomarkers for diagnosis of ancient TB.  
Rib bone samples from individuals who died between 1910 and 1936 (48% being 
associated with TB as a cause of death after clinical examination) were processed 
and analyzed by normal phase HPLC. 33% of the 49 samples were negative for the 
analysis. For the positive samples, C32, C29 and C30 mycocerosates, were the 
major components detected. In this study the detection of C27 mycolipenates (a 
multimethyl-branched group of fatty acids present in the TB cell wall) was also 
achieved (Redman et al., 2009). A characteristic feature of M. ulcerans is the 
production of the lipidic-nature toxin mycolactone. Skin samples from M. ulcerans-
infected patients were analyzed by using TLC and MS. Mycolactone was detected 
from early to ulcerative lesions and also from lesions from patients under antibiotic 
therapy (Sarfo et al., 2010). 
 
4.2 Mycolic acids as biomarkers for Mtb detection 
Given the MAs role in immunogenicity and pathogenicity, they have been 
used as antigens for the serodiagnosis of TB. However, the sensitivity of the assays 
has been postulated to be affected by the interaction of MAs with cholesterol. A 
similar structural conformation and attraction between free carboxylic group of 
individual MAs was also proposed as a reason the poor sensitivity of the ELISA tests 
(Benadie et al., 2008). Another approach for the antibody detection is the use of MAs 
liposomes immobilized on a biosensor cuvette that allow to monitor and quantify the 
interaction of analytes in real time (Thanyani et al., 2008). 
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The different classes of MAs can be separate using normal TLC, however, the 
profile is not a diagnostic criteria for the Mtb complex because it is shared with other 
mycobacterial species. The use of reverse HPLC allows the separation by length 
and polarity, producing characteristic peaks to identify Mycobacterium species by the 
different profiles obtained (Buttler et al., 2001). Moreover, HPLC coupled to MS can 
produce an improvement in MA detection by providing accurate molecular weights 
(Shui et al., 2007; Minnikin et al., 2010). The presence of MAs in biological fluids has 
been studied in sputum samples from TB patients. MAs converted to anthrylmethyl 
esters were detected using fluorescence HPLC obtaining characteristic profiles for 
these lipids (Minnikin et al., 1993). The use of ESI/MS has also been applied for the 
direct measurement of MAs in sputum samples (Shui et al., 2011). To evaluate the 
use of MAs as biomarkers for diagnosis and drug therapy monitoring, Shui et al. 
(2011) analyzed sputum based in a retrospective, multi-center, case control study 
using MS. Non-oxygenated MAs with C26  -chains were the best MAs biomarkers to 
classify active versus non-active (cured) patients originating from South Africa, 
Vietnam and Uganda. For monitoring drug efficacy, lung tissue of mice infected with 
Mtb was analyzed for MAs presence and compared with mice infected with Mtb, 
treated with RIF until obtaining negative culture for Mtb. Results showed a decrease 
of MAs in the last mentioned group. However, when the Korean patients study was 
performed, no differences were observed in MAs profiles between infected 
individuals who received anti-TB chemotherapy and those who did not. 
Analysis of archeological samples can provide important information about 
ancient microorganisms and the tracking of their evolution using molecular 
techniques. The study of TB in archeological samples can be performed by the 
analysis of morphological changes in skeletal material, like spinal destruction. 
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However, the specificity of the diagnosis using these parameters can be affected by 
other diseases that cause similar physiological changes (Redman et al., 2009). 
Skeletal remains dating from 9250-8160 years ago of a woman and a child with 
characteristic lesions of TB were analyzed by HPLC and PCR to explore the use of 
MAs as biomarkers. The results showed the characteristic profile for α, keto and 
methoxy mycolates using normal and reverse phase HPLC. Mtb complex DNA was 
detected giving positive results for the multi-copy IS6110 and IS1081 (Hershkovitz et 
al., 2008). These data not only help to validate MAs as robust markers of TB, but 

















5. Project Rationale 
Development of new tools for the diagnosis and control of TB is a major 
challenge. In this context the use of biomarkers can be applied for detecting 
characteristic signatures from the pathogen. The unique and rich lipid profile of the 
mycobacterial cell wall make it an interesting target for lipidomics studies and the 
analysis of biomarkers that can be used in diagnosis or prognosis of drug efficacy in 
TB infected patients. If a specific biomarker or set of biomarkers are identified to 
have a good correlation with the clearance of the disease, they can be measured 
after the establishment of the treatment to evaluate the progress of the treatment 
and identify if the drug is being effective or not. 
MAs represent an important percentage of the Mtb cell wall and are 
characteristic of this pathogen. These lipids have been detected in clinical samples 
such as sputum, by using LC-MS. However, analyses in other biological fluids such 
as serum or urine from TB patients are still unavailable. 
Biological fluids can be challenging for the detection of MAs using LC-MS, 
mainly because of many compounds compete in the ionization process and those in 
less abundance can be in a detrimental situation with respect to the more abundant 
compounds. In this scenario, the derivatization of chemical structures can be used 
as a tool to improve the sensitivity of the LC-MS technique. Fatty acids are 
comprised in their structure of carboxylic acids, this fact make them negatively 
charged through deprotonation of the acidic group and as a result they can be 
analyzed in the negative-ion mode by MS (Cech et al., 2002). However, the 
detection sensitivity and specificity can be affected because of the high background 
noise (Santa et al., 2007). Ionization efficiency is related to quantification in LC/MS. 
Matrix suppression of ionization can greatly reduce sensitivity and complicate 
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quantification. Ionization efficiency of analytes can be variable, depending on the 
concentration of other analytes in the mixture that could suppress their ionization. 
Increasing the ionization is one way to subvert these problems; this can be achieved 
by using derivatization methods to improve the ionization (Yang et al., 2007). 
Chemical derivatization involves a reaction between the analyte molecule and the 
derivatization reagent. For LC/MS it is common to incorporate cationic groups for 
positive-ion mode and strongly acidic groups for negative-ion mode, or other groups 
that improve ionization (Eggink et al., 2010). As a consequence of the derivatization 
process, the physical and chemical properties of the analyte change, allow an 
increase in the ionization efficiency. Another advantage of the derivatization process 
is the change in the chromatographic retention of the analyte, reducing the 
suppression of ionization due to the presence of molecules that co-elute with the 
target analyte (Gao et al., 2005).  
There are different ways to derivatize compounds that are comprised of 
carboxylic acids in their structure (Santa et al., 2010). In the case of MAs, phenacyl 
esters have been used to improve their detection by HPLC utilizing UV detection 
(Butler et al., 2010). Also methyl esters of MAs have been used for TLC and MS 
analysis. By the methyl esterification of the carboxylic acid, the MAs can separate 
properly by TLC avoiding interactions with the silica that make separation incomplete 
(Laval et al., 2001). As it was mentioned, enhancement of ionization efficiency is one 
of the final purposes when derivatization protocols are used. Yang et al., (2007) 
studied a derivatization protocol for fatty acids from C10 to C24 by adding a positive 
charge through the introduction of a quaternary amine. The detection of the fatty 
acids using the positive ionization mode, allowed a 2,500 fold enhancement of the 
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fatty acid detection, comparing the derivatized fatty acid in positive mode versus the 
non- derivatized in negative mode.  
We hypothesize that enhanced detection of MAs will be achieved in the 
positive ion mode by applying the chemical derivatization method described by Yang 
et al., (2007). By using this method, a quaternary amine is expected to be attached 
to the carboxylic group of the MA structure, giving a positive charge to the 
compound, and allowing an improvement in the MA ionization that will be refelected 
















6. Material and methods 
6.1 Material and reagents 
6.1.1 Material 
  The MA standard used during this study was extracted from Mtb strain H37Rv 
as is explained in section 6.2. To test the derivatization protocol the MA standard 
was considered as a sample to be derivatized. MA standard was also used to spike 
human urine and human serum previous the derivatization process. Serum was 
purchased from Sigma-Aldrich (St. Louis, MO) and urine from Gemini-Bio products 
(West Sacramento, CA). 
 
6.1.2 Reagents  
2-bromopyridine, 3-carbinolpyridine, triethylamine (TEA), iodo- methane, 
ammonium acetate, potassium hydroxide, hydrochloric acid, and sodium dodecyl 
sulfate were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile, water, 
acetone, chloroform, methanol, hexane, and n-propyl alcohol were purchased from 
Honeywell Burdick and Jackson (Muskegon, MI) and diethyl ether from Alfa Aesar 
(Ward Hill, MA). All the chemicals were analytical or LC-MS grade.  
 
6.2 Extraction and purification of mycolic acids 
Mtb strain H37Rv is the reference strain used worldwide to study the 
pathogenesis and virulence of Mtb. It was originally isolated from a chronic case of 
pulmonary TB in 1905. Since then, the strain has been maintained and currently is 
part of the American Type Culture Collection (ATCC) (Zheng et al., 2008).  
MAs were extracted from an ATTC reference strain to perform the different 
experiments during this study. 
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6.2.1 Extraction of the mycolic acid-peptidoglycan-arabinogalactan (mAGP) 
complex 
For the MAs extraction, 13.325 g (dry weight) of Mtb cells (H37Rv) that had 
been delipidated with chloroform: methanol (2:1 v/v) were split into two Oakridges 
tubes and suspended in 30 ml of HPLC water. The main goal of the initial process is 
to remove proteins and free lipids from the mAGP. For this, 30 ml of 2% sodium 
dodecyl sulfate (SDS) were added to each tube, stirring them at room temperature 
for 30 minutes followed by centrifugation at 27,000 xg at 25°C for 10 minutes. The 
supernatants were decanted and the SDS wash was repeated. After this, 20 ml of 
2% SDS plus 1 ml (5 mg) of proteinase K (Promega, Madison, WI) were added. The 
samples stirred at room temperature for 10 minutes. The samples were centrifuged 
at 27,000 xg for 10 minutes and the supernatants were decanted and 20 ml of 2% 
SDS were added to the pellets. Samples were stirred at 90°C for one hour and 
centrifuged at 27,000 xg, at 25°C for 10 minutes. The SDS wash at 90°C was 
repeated twice. The SDS extracted pellets were washed with 30 ml of HPLC water (8 
times). To remove residual SDS the water washed pellets were extracted with 30 ml 
80% acetone (x2) and 30 ml of 100% acetone (x1). The fully extracted mAGP was 
placed in a chemical fume hood and allowed to dry.  The purified mAGP was transfer 
to a new pre-weighted 16 x 100 mm glass tube (Daffe et al, 1990).  
 
6.2.2 Base hydrolysis of mAGP 
Aliquots of mAGP (50 to 100 mg) were placed into 16 x 100 mm glass tubes. 
1M potassium hydroxide (2ml) in methanol was added per tube and allowed to react 
for 2 h at 80°C. HPLC water (2.5 ml) was added, the pH was adjusted to 
approximately 3.0 with 6 N HCl, and the saponified material was extracted twice with 
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4.5 ml of diethyl ether. The upper layer of diethyl ether for each extraction was 
collected after centrifugation at 2,800 xg at 20°C for 5 min. The ether fractions were 
pooled and back extracted with HPLC water. The final organic phases were transfer 
to a pre-weighted 16 x 100 mm glass tube and dried under nitrogen. 89.6 mg of MAs 
were obtained and dissolved in 1 ml of chloroform/methanol (2:1 v/v). Subsequently, 
100 µl of MAs were applied to C-18 Sep-Pak® Vac RC 100mg cartridges (Waters 
Corp., Milford, MA) equilibrated with 5 ml of 100% methanol. The elution process 
was comprised of three steps: (i) 5ml of methanol, (ii) 5 ml of methanol: n-propanol: 
hexane (20:4:1 v/v), and (iii) 5 ml of n-propanol: hexane (80:20 v/v). The third 
fraction contained the MAs and was dried under nitrogen to use as a standard. A 
total of 77.4 mg of MAs were recovered and the purity was checked by LC/MS as 
described in section 10.4 (Bhamidi et al, 2011). 
 
6.3 Synthesis of derivatizing reagents 2-Bromo-1-methylpyridinium Iodide 
(BMP) and 3-Carbinol-1-methylpyridinium Iodide (CMP) 
To generate BMP and CMP the protocol of Yang et al (2007) was followed. 
Briefly, five-fold excess of iodomethane was added to 2-bromopyridine (10 mmol, 
0.97 ml) or 3-carbinolpyridine (10 mmol, 0.96 ml). The solution was stirred at room 
temperature for 1 h. Afterwards the crystals were washed with cold acetone, and 
dried. The crystals of BMP and CMP were suspended in acetonitrile to a final 
concentration of 50 µmol/ mL and 200 µmol/ mL, respectively. The reagent solutions 
were freshly prepared before derivatization and were not used longer than a week to 




6.4 HPLC ESI/APCI-MS 
An Agilent 1200 HPLC (Agilent Technologies, Palo Alto, CA) equipped with a 
Waters XBridge C18 column (2.1 x 150 mm, 3.5 µm) was used for chromatographic 
separation of MAs using a gradient of 100% of solvent A (99% methanol, 1% 5 mM 
ammonium acetate) to 100% solvent B (79% n-propyl alcohol, 20% hexane, 1% 5 
mM ammonium acetate) at a temperature of 45 °C. The flow rate was of 0.32 ml/min 
for a total run time of 45 min. The ESI/APCI-MS was performed on an Agilent 6220 
column and the multimode source (ESI/APCI) was operated in the positive and 
negative ion mode. The drying gas temperature was 300°C, and the vaporizer 
temperature was set at 200°C. The fragmentor voltage was set to 120 V and the 
mass spectrum was acquired from m/z 250 to 3200 Da with a frequency of 1 scan/s. 
An Agilent tune mix (Lot LB91098) was used for mass calibration and the data was 
collected with the Agilent MassHunter WorkStation Data Acquisition software version 
B.02.00 (Sartain et al, 2011). 
 
6.5 Tandem mass spectrometry  
An Agilent 6520 qTOF was used for MS/MS analysis of derivatized MA 
standard. Positive ion mass spectra were acquired in auto MS/MS form.  The 
instrument was set up by using same parameters described on 6.4, except for the 
following: drying  gas temperature was 310°C and the OCT RF was set at 750 V. 
Collision energies with slope of 6.5 V/100 Da and offset 2.0 V were used for 




6.6 Sample derivatization 
Testing of the solvents to be used during the MAs derivatization process was 
performed by comparing chloroform: methanol (2:1 v/v) and chloroform: acetonitrile 
(2:1 v/v). One of the samples included 2.5 nmol of MAs and derivatizing reagents 
BMP and CMP suspended in chloroform: methanol (2:1 v/v). The other sample 
included 2.5 nmol of MAs and derivatizing reagents BMP and CMP suspended in 
chloroform: acetonitrile (2:1 v/v). The ion volume of the MAs comprised in α-, keto- 
and methoxy-class was recorded to compare the two different methods. Samples 
were analyzed in duplicate.   
For the derivatization reaction all the samples were analyzed in triplicate. The 
samples included MAs standard (6 dilutions from 1 pg/10 µl to 100 ng/10 µl), urine 
samples spiked with the MAs standard (6 dilutions from 100 pg/10 µl to 10 µg/10 µl) 
and serum samples spiked with MAs standard (6 dilutions from 1 ng/10 µl to 100 
µg/10 µl). 
Samples (10 ul) were derivatized with 20 l of BMP, 20 l of CMP and 1 l of 
triethylamine (TEA). Samples were incubated in a water bath at 50°C for 30 minutes 
(Yang et al, 2007). After the derivatization an additional cleaning step was performed 
to remove excess derivatizing reagents. Samples were dried under nitrogen and 
suspended in 100 l of acetonitrile, after homogenization the solvent was removed 
and the cleaning process was repeated followed by drying of the samples under 
nitrogen. Finally samples were suspended in 51 l of chloroform: acetonitrile (2:1 




6.7 Mycolic acid extraction from serum samples 
C-18 Sep-Pak® Vac RC 100 mg cartridges were used to enrich the sample 
and the MAs spiked into human serum (Aldrich) samples. Different concentrations of 
MAs prepared in a final volume of 10 l of chloroform: methanol: water (10:10:3 v/v) 
and spiked into 90 l of human serum. The samples were loaded onto the C-18 
cartridges equilibrated with 5 ml of methanol. Three fractions were obtained by 
elution with (i) 5ml of methanol, (ii) 5 ml of methanol: n-propanol: hexane (20:4:1 
v/v), and (iii) 5 ml of n-propanol: hexane (80:20 v/v). The third fraction containing the 
MAs was dried under nitrogen and suspended in 51 l of chloroform: acetonitrile (2:1 
v/v) for LC/MS analysis in (+) and (-) ionization mode (Bhamidi et al, 2011; Sartain et 
al, 2011). 
 
6.8 Mycolic acid extraction from urine 
MAs were prepared at different concentrations and suspended in a final 
volume of 10 l chloroform:acetonitrile (2:1 v/v) to be spiked into 990 l ml of human 
urine (Gemini-Bio Products).  The lipid extraction was performed by adding 3 ml of 
chloroform: methanol (2:1 v/v). Afterwards they were vortexed and incubated for one 
hour at room temperature. HPLC grade water (0.5 ml) was added and samples were 
centrifuged at 1,800 xg at 20°C for 10 min and the upper layer was removed. 
Following this, 0.5 ml of upper Folch‘s solution (chloroform: methanol: water in a ratio 
of 3:47:48 v/v) was added, and samples were vortexed and centrifuged at 1,800 xg 
at 20°C for 10 min (Khan et al, 2002). The chloroform fraction was recovered and 
samples were dried under nitrogen. Finally, samples were suspended in 51 µl of 




6.9 Method validation 
Estimation of method detection limit (MDL) was made according to the 1996 
analytical detection limit guidance (Wisconsin Department of Natural Resources 
Laboratory Certification Program) and included seven replicates for the blank and 
seven replicates for the sample in study. The standard deviation (SD) and the 
Student‘s t value for the appropriate degree of freedom were used to calculate the 
MDL with a 99% confidence limit.  
 
6.10 Data processing and analysis 
For the analysis of the data files, the MassHunter Qualitative Analysis 
Software version B.02.00 (Agilent Technologies, Santa Clara, CA) was used. 
Molecular features (MFs) were extracted using the Molecular Feature Extraction 
(MFE) algorithm, and the Mtb LipidDB was used for the MAs identification (Sartain et 
al, 2011). The identification of the MAs by using the database is based in the exact 
mass of the compound. Mtb LipidDB was extended by adding the protonated mass 
for MAs in (+) mode. Another database was created with Microsoft Excel 2007 Pro 
(Microsoft, Redmond, WA) to detect derivatized MAs by adding the AMMP mass and 
the different possibilities for adduct formation in the (+) ionization mode. The MFE 
features used for the data analysis included the ion volume value for the different 
MAs compounds and the retention time. 
 
6.10.1 Statistical analysis 
The non-parametrical test Kruskal-Wallis was used to compare the median 
ion volume value of MAs between the following groups:  i) MAs non-derivatized in (-) 
mode, ii) MAs non-derivatized in (+) mode, and iii) MAs derivatized (+) mode. The 
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null hypothesis stated that the ion volume for the MAs was the same for the three 
groups analyzed. Where between-group differences were detected (null hypothesis 
for Kruskal-Wallis rejected) the Nemenyi test was used to identify which of the 
analyzed groups were significantly different. Kruskal-Wallis and Nemenyi test were 
also used to analyzed MAs individually, by comparing the ion volume value of 























7.1. Mycolic acid standard derivatization 
7.1.1 The derivatization reaction 
The protocol of Yang et al. (2007) was followed for the derivatization process. 
As shown in Figure 3, the reaction of the carboxylic group of MAs with the 
derivatizing reagents produces the final product of 3-acyl-oxymethyl-1-
methylpyridinium iodide (AMMP) that should provide a (+) charge to the MA 
structure. 
           
Figure 3. Derivatization reaction of mycolic acids. 2-Bromo-1-methylpyridinium 
Iodide (BMP), 3-Carbinol-1-methylpyridinium Iodide (CMP), triethylamine (TEA), 
R=MA, 3-acyl- oxymethyl-1-methylpyridinium iodide (AMMP). The carboxylic group 
of R reacts with TEA, removing a proton from the carboxylic group. Subsequently 
there is a formation of an ester linkage between BMP and R, forming the 
intermediate compound (I). TEA removes a proton from CMP, because of the 
electronegative nature of CMP, it is going to attract the intermediate compound I, 














producing the final product AMMP (II). Adapted with permission from Yang et al, 
2007. Copyright 2012 American Chemical Society. 
 
7.1.2 Solvent testing solubility during the mycolic acids derivatization reaction 
Yang et al. (2007) applied the derivatization AMMP protocol to fatty acids 
ranging from C10 to C24 and used acetone as a main solvent to solubilize the fatty 
acids. A modification of the protocol was considered, mainly because of the fact that 
MAs have a much longer carbon chain (C60 to C90), and less polar solvents are 
needed to solubilize them properly, this fact was confirmed by the poor solubilization 
of MAs in acetone (data not shown). A first approach was to test the solubility of the 
different compounds involved in the reaction by using different solvents. For this, two 
facts were considered (1) a mixture of chloroform: methanol (2:1 v/v) is usually used 
to solubilize the less polar MAs (Bhamidi et al, 2011) and (2) the more polar 
derivatizing reagents BMP and CMP are soluble in acetonitrile (Yang et al, 2007). 
Therefore the solvent mixtures to be tested were comprised of a more polar and a 
less polar solvent to achieve the solubilization of all the compounds during the 
derivatization reaction. 
Two solvent mixtures were tested in duplicate: (1) chloroform: methanol (2:1 
v/v) and (2) chloroform: acetonitrile (2:1 v/v). The derivatizing reagents BMP and 
CMP and MAs (2.5 nmol) were prepared using acetonitrile and chloroform: methanol 
(2:1 v/v) respectively. After this they were dried under nitrogen and the two different 
solvent mixtures were tested during the derivatization process and analyzed by 






Figure 4. Flow chart of the derivatization reaction comparing two solvents. 
Two solvents were compared (1, left side of flow chart) chloroform: acetonitrile (2:1 
v/v) and (2, right side of flow chart) chloroform:methanol (2:1 v/v). (*) derivatizing 
reagents were originally suspended in acetonitrile and then dried under nitrogen and 
suspended in solvent 1 (*1) or 2 (*2). 
 
 
The ion volume value, referred to as the total ion volume of all the peaks 
associated with the respective compounds (m/z x retention time x abundance) was 
2.5 nmol MAs (0.07 g) 
In 10 l chloroform:methanol (2:1 v/v) 
Dry under nitrogen 
Suspended in 10 l 
Chloroform:acetonitrile (2:1 v/v) 
+ 20 l BMP 
+ 20 l CMP 
(1) 
+ 20 l BMP 
+ 20 l CMP 
+ 1 l TEA + 1 l TEA 
Incubate for 30 minutes at 50°C Incubate for 30 minutes at 50°C 
LC/MS analysis 
Volume of injection 10 l 
LC/MS analysis 
Volume of injection 10 l 
(*1) (*2) 
Suspended in 10 l 




determined for the different mycolate classes by using the MFE of the Mass Hunter 
Agilent software. The use of chloroform:acetonitrile (2:1 v/v) improved the total ion 
volume value for the -, keto- and methoxy- mycolate classes compared to the use 
of chloroform: methanol (2:1 v/v). Thus chloroform:acetonitrile (2:1 v/v) was chosen 




Figure 5. Comparison of solvents performance during MAs derivatization 
reaction. The ion volume of the different mycolate classes are shown, comparing 
the use of chloroform: methanol (2:1 v/v), and chloroform: acetonitrile (2:1 v/v). 
Results correspond to the average ion volume of duplicate samples. 
 
 
7.1.3 Tandem mass spectrometry of derivatized mycolic acids 
Because of the chemical structure of the MA, the attachment of the 






















chain. To confirm this, 10 µg/10 µl of the MAs standard were derivatized and 
analyzed by tandem mass spectrometry (Figure 6). Collision-induced fragment ion 
spectra for different derivatized MAs showed common ions at m/z 107 and 502. The 
m/z 107 ion derived from the N-pyridylcarbinol moiety and the m/z 502 represented 





Figure 6. ESI tandem mass spectra showing fragmentation of α-C78 (m/z 
1243.2427) Collision energy was applied to α-C78 (m/z 1243.27). Two fragments 
were identified as 107.0698 corresponding to the quaternary amine mass and 
502.443 corresponding to the α-chain of the MA (24 carbon) plus the mass of the 
quaternary amine. 
 
7.1.4 Cleaning of the sample from derivatizing reagents  
The mass spectrometer resolution (ion separation power) was affected after 
the execution of preliminary derivatization experiments. This appeared to be a 




capillary inside the mass spectrometer. Thus to remove excess of derivatizing 
reagents, a cleaning procedure for the sample after the derivatization reaction was 
developed and tested. 
For cleaning purposes, acetonitrile was used because of its ability to solubilize 
the derivatizing reagents and because MAs were not expected to be solubilized in 
this solvent. Sample, control and blank were analyzed in triplicate to evaluate the 
method as described in Table 1.  
 
Table 1. Cleaning of the sample after derivatization  
Sample Control Blank 









20 µl BMP+20 µl CMP+ 
1 µl TEA 
20 µl BMP+20 µl CMP+ 
1 µl TEA 
 
Incubate 30 min at 50°C  
Wash 1:  
100 µl acetonitrile 
 
Wash 2:  
100 µl acetonitrile 
 
Wash 3:  
100 µl acetonitrile 
Incubate 30 min at 50°C 
Wash 1:  
100 µl acetonitrile 
 
Wash 2:  
100 µl acetonitrile 
 
Wash 3:  
100 µl acetonitrile 
Incubate 30 min at 50°C 
Wash 1:  
100 µl acetonitrile 
 
Wash 2:  
100 µl acetonitrile 
 
Wash 3:  
100 µl acetonitrile 
 
 
After the incubation step (30 min at 50°C), samples were dried under nitrogen 
and suspended in 100 µl of acetonitrile and homogenized. The acetonitrile wash was 
collected, dried under nitrogen and the resulting residue suspended in 100 µl of 
water. Two additional washes were performed and processed in the same manner. 
The UV spectrum (230 to 400 wavelength) was measured for the samples dissolved 
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in water using a multi-detection microplate reader (BioTek®) and the absorbance for 
























Figure 7. Cleaning process for derivatized samples.Samples were washed with 
acetonitrile. A=First acetonitrile wash, B= Second acetonitrile wash, C= Third 
acetonitrile wash. Mean maximum (max) and minimal (min) optical density (OD) are 
showed for derivatized sample (----), control sample (----) and blank (----). 
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After the first wash with acetonitrile higher values for the mean maximum 
(Max) optical density (OD) for the derivatized sample and the control sample were 
observed compared to the blank (Figure 7 A). This pointed to the removal of 
derivatizing reagents that was also observed in the second wash (Figure 7 B), but in 
a lower intensity. Samples did not show major difference with a third acetonitrile 
wash (Figure 7 C). Based these results it was decided that all derivatized samples 
would be extracted twice with acetonitrile prior to analysis of LC/MS. 
 
7.2 Comparison of derivatized and non-derivatized mycolic acid standard 
The MA standard used was obtained as described in section 6.2. Serial 
dilutions 1:10 in the range of 100 ng to 1 pg/10 l (total weight) of non-derivatized 
and derivatized MAs standard were analyzed by LC/MS. Chloroform: methanol (2:1 
v/v) was used as a solvent to perform the dilutions. After this, the dilutions were dried 
under nitrogen and suspended in chloroform: acetonitrile (2:1 v/v) to use the same 
solvent for the derivatized and non-derivatized samples.  
To perform the derivatization reaction of MAs standard, 10 µl of each dilution 
were derivatized by using 20 ul of each derivatizing reagent (BMP and CMP) plus 1 
µl of TEA. Samples were incubated at 50°C for 30 min and then they were dried and 
cleaned twice with 100 µl of acetonitrile. After this process, samples were suspended 
in 51 µl chloroform: acetonitrile (2:1 v/v) and analyzed in the (+) ionization mode. 
The different dilutions for non-derivatized MAs were analyzed by LC/MS in the 
(+) and (-) ionization mode. The MFE algorithm from the Agilent MassHunter 
software along with the use of the Mtb LipidDB (Sartain et al, 2011) allowed for the 
identification of the different MAs compounds. An extension of the database was 
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performed to be able to identify protonated MAs in the (+) mode and derivatized 
MAs. 
As a first approach the main MAs were identified. The retention time (Rt), 
which is the time for a compound to be eluted from the chromatographic column, 
ranged between 17 and 22 min for the different mycolate classes. This 
chromatographic range was analyzed to compare the major ions. Non-derivatized 
MAs standard in (-) mode and derivatized MAs in (+) mode shared a similar profile, 
where the major ions corresponded to -C78, -C80, -C82, methoxy-C83, 
methoxy-C85 and methoxy-C87. Within the keto-mycolate class, the ions for keto-
C84 and keto-C86 were the most abundant, but the relative intensity was less 
compared to the ions of the - and methoxy-MAs (Figures 8 A and 8 B). Shui et al. 
(2011) analyzed by LC/MS an Mtb Beijing strain culture in the (-) ionization mode 
and showed that ions correspond to -C78, methoxy-C85 and keto-C84 were the 
most abundant. Despite the fact that a different Mtb strain was used in our study 
(H37Rv) the results of the major ions profile was similar for the (-) mode.  
When the same analysis was performed for non-derivatized MAs in (+) mode, 
the profile was different, -C79, -C81, keto-C85, keto-C87, methoxy-C86, and 
methoxy-C88 were the major ions with a higher relative intensity for the - and 
methoxy-class and a lower for the keto-class (Figure 8 C). Regarding the profile of 
MAs ions in the (+) mode it was important to consider the presence of additional 
adducts, generally ESI result in protonated (M+H)+ molecules in the (+) ion mode; 
however, some molecules can be also ionized as (M+Na)+, (M+K)+, or (M+NH4)
+. 
The elements involved in the adduct formation can originate from glassware or 
impurities in the chemical solvents, or from their addition to the mobile phase 
(Mortier et al, 2004). In the case of MAs, (M+Na)+ and (M+NH4)
+ adducts were 
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observed in the (+) ionization mode (Figure 8 D). The summation of all ion adducts 
can help to reduce the variation (Mortier et al, 2004) and this approach was used for 
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Figure 8. Extracted ion chromatogram for derivatized and non-derivatized MAs 
(Rt 17-22 min). The profile of the major ions is shown for non-derivatized MAs (-) 
mode (A), derivatized MAs (+) mode (B), non-derivatized MAs (+) mode (C). An 
example of adduct formation for α-C78 non-derivatized MA is shown in panel D in 
the (+) mode with the protonated form and the (M+Na)+ and (M+NH4)+ adducts. MAs 
concentration analyzed were 100 ng/10 µl. 
 
MAs are usually analyzed in (-) mode. Thus, the profile of the most abundant 
MAs in (-) mode was selected to compare with derivatized and non-derivatized MAs 
in the (+) mode. The profile was comprised of -C78, -C80, -C82, methoxy-C83, 













Table 2. Mycolic acid profile used to compare between derivatized and non-
derivatized samples1.  
 
1 The summation of all adducts were used for quantitative comparisons, but only the 




In the case of the MAs standard derivatization, the addition of a quaternary 
amine to the MA structure increased the mass of all MAs by 106.065126 amu 
(atomic mass units), the derivatization also resulted in a shift in the Rt for the 
derivatized compounds explained by the increasing mass (Figure 9).  
MA 
Non-derivatized MAs (-) 
mode   
Non- derivatized MAs 
(+) mode 









   
Alpha-MA (C78) 1136.1663 [M-H]- 18.907   1138.1809 [M+H]+ 18.833   
Alpha-MA (C80) 1164.1977 [M-H]- 19.381   1166.2125 [M+H]+ 19.302   
Alpha-MA (C82) 1192.2285 [M-H]- 19.84   1194.2433 [M+H]+ 19.7   
Keto-MA (C84) 1236.2547 [M-H]- 17.703   1238.2683 [M+H]+ 17.636   
Keto-MA (C86) 1264.2862 [M-H]- 18.174   1266.3005 [M+H]+ 18.103   
Methoxy-MA (C83) 1224.2552 [M-H]- 18.7   1226.2702 [M+H]+ 18.638   
Methoxy-MA (C85) 1252.287 [M-H]- 19.159   1254.2996 [M+H]+ 19.086   
Methoxy-MA (C87) 1280.3181 [M-H]- 19.599   1282.3342 [M+H]+ 19.538  
         
MA            Derivatized MAs (+) mode      





      
Alpha-MA (C78) 1243.23 [M+AMMP]+ 20.404      
Alpha-MA (C80) 1271.26 [M+AMMP]+ 20.853      
Alpha-MA (C82) 1299.3012 [M+AMMP]+ 21.298      
Keto-MA (C84) 1343.326 [M+AMMP]+ 19.228      
Keto-MA (C86) 1371.3579 [M+AMMP]+ 19.666      
Methoxy-MA (C83) 1331.3269 [M+AMMP]+ 20.192      
Methoxy-MA (C85) 1359.3584 [M+AMMP]+ 20.609      




Figure 9. Retention time and m/z of derivatized and non-derivatized MAs. A shift 
in the m/z and Rt was observed between non-derivatized MAs in (+) and (-) mode 
and derivatized MAs in (+) mode. MAs profile included -C78, -C80, -C82, keto-
C84, keto-C86, methoxy-C83, methoxy-C85, and methoxy-C87. 
 
 Non-derivatized MAs in (+) and (-) mode shared a similar chromatographic 
profile (Figure 10) for keto-C84, keto-C86, methoxy-C83, -C78, methoxy-C85, -80, 
and methoxy C-87. Other non-derivatized MAs such as keto C-85, keto C-87, 
methoxy C-84, methoxy C-86, methoxy- C88, methoxy- C90 showed a visible signal 
in the (+) mode, but not in the (-), this fact pointed to a broader signal spectra for 
non-derivatized MAs in the (+) mode. The derivatized MAs sample showed an 
enhancement of the signal compared to the non-derivatized samples, and a shift of 







































Figure 10. Extracted ion chromatogram (1000-1500 m/z) for derivatized and 
non-derivatized MAs.100 ng/10 l of MAs were analyzed. Non-derivatized MAs in (-
) mode (pink line), non-derivatized MAs in (+) mode (black line) and derivatized MAs 
in (+) mode (blue line). Capital letters indicate base peak A, (keto-C84); B, (keto-
C86); C, (methoxy-C83); D, (α-C78); E, (methoxy-C85); F, (α-C80); G, (methoxy-
C87); H, (keto-C85); I, (keto-C87); J, (methoxy-C84); K, (methoxy-C86); L, (methoxy-
C88); and M, (methoxy-C90). 
 
 
The Hypothesis of this study states that the ionization efficiency of MAs could 
be improved by the addition of a positive charge. To compare the absolute 
abundance of derivatized and non-derivatized MAs the extracted ion chromatograms 
B C 










(m/z 1000 to 1500) were analyzed. The intensity of the signal was higher for the 
derivatized compounds when high concentrations of MAs (100ng/10ul), and lower 
concentrations of MAs were compared (1 ng/10 ul), the signal was remained higher 
for derivatized MAs as compared to the underivatized MAs analyzed in the (+) or (-) 
ion modes (Figure 11). 
The median ion volume value between derivatized and non-derivatized MAs 











Figure 11. MAs extracted ion chromatogram (1000-1500 m/z). Analysis of 100 
ng/10 l (A) and 1ng/10 l (B) of MAs were analyzed. Results show samples in 
triplicate for non-derivatized MAs in (-) mode (pink line), non-derivatized MAs in (+) 
mode (black line) and derivatized MAs in (+) mode (blue line). An enhancement of 







Figure 12. Ion volume comparison between derivatized and non-derivatized 
MAs at 100 ng/10 µl (A), and 1 ng/10 ul (B).The chart was constructed by using the 
median ion volume value for the MAs analyzed in triplicate. 
 
For statistical purposes three groups were compared i) non-derivatized MAs (-
) mode, ii) non-derivatized MAs (+) mode, and iii) derivatized MAs (+) mode. The 















Mycolic acid compound 
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and 1 ng/10µl (Table 3) to analyze the differences of the median ion volume value 
between the groups. By using the Kruskal-Wallis test the median ion volume for 
individual targeted MAs were ranked and differences were observed between the 
three groups. Thus, based on these rankings the Nemenyi test was applied to 
identify which of the analyzed groups were significantly different. 
  
Table 3. Analysis of MAs standard by using Kruskal Wallis test1.  
   MA 100 ng/10 µl 
(Group i) 











          
Alpha-MA (C78) 2725187 (22) 1652858 (15) 1355323 (10) 
Alpha-MA (C80) 2119315 (21) 1899749 (19) 1327511 (9) 
Alpha-MA (C82) 896479 (6) 772425 (5) 263167 (2) 
Keto-MA (C84) 1007249 (8) 1424689 (13) 244466 (1) 
Keto-MA (C86) 1374523 (11) 1758604 (18) 406463 (3) 
Methoxy-MA (C83) 1545374 (14) 932925 (7) 499497 (4) 
Methoxy-MA (C85) 3127690 (24) 2036600 (20) 1395801 (12) 
Methoxy-MA (C87) 2746551 (23) 1724695 (17) 1654712 (16) 
 
MA 1 ng/10 µl 
(Group i) 
MAs standard  
non-derivatized 









          
Alpha-MA (C78) 169064 (22) 202599 (24) 69054 (12) 
Alpha-MA (C80) 150122 (21) 186555 (23) 80552 (14) 
Alpha-MA (C82) 50312 (9) 92053 (15) 27355 (5) 
Keto-MA (C84) 25107 (4) 62812 (11) 0 (1) 
Keto-MA (C86) 42774 (7) 106517 (16) 0 (2) 
Methoxy-MA (C83) 46036 (8) 28221 (6) 0 (3) 
Methoxy-MA (C85) 139585 (18) 141391 (20) 61805 (10) 
Methoxy-MA (C87) 133485 (17) 139620 (19) 73943 (13) 
 
1The ion volume median value for the different MAs analyzed in triplicate is shown 
(with ranks of the data in parentheses). The higher the number the greater the rank. 
MAs concentration analyzed correspond to 100 ng/10 µl and 1 ng/10ul (α=0.05). 
By using the Nemenyi test for the analysis of the higher concentration of MAs 
(100 ng/10 µl), the ion volume value for the group i) was significantly higher 
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compared to the group iii). There were no significant differences between groups i) 
and ii) or between groups ii) and iii) (Figure 13 A). 
The analysis of the lower MA concentration (1 ng/10 µl) showed that the ion 
volume value for the group ii) was significantly higher compared to group iii). There 
were no significant differences between groups i) and ii) or between groups i) and iii) 
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Figure 13. Significant differences in ion volume between groups based on the 
Nemenyi test. A (100 ng/ 10 µl), B (1 ng/ 10µl). Number 1 and 24 identify the lower 
and higher ion volume ranking for MAs in group i) non-derivatized MAs (-) mode, 
group ii) non-derivatized MAs (+) mode, and group iii) derivatized MAs (+) mode. 
Brackets between groups indicate significant differences in ion volume. The MAs 
standard concentrations were 100 ng/10µl (A) and 1 ng/10µl (B). 
 
The analysis described above did not provide information about individual 
MAs, because of this, it was important to analyze the eight MAs separately by 
applying the same statistical analysis. In this way, each MA was compared in i) non-
derivatized (-) mode, ii) non-derivatized (+) mode, and iii) derivatized (+) mode. The 
ion volume value of triplicates was used for each MA, considering 100 ng/10 µl and 1 
  
 Group iii  




 Group iii  





ng/10 µl concentration. Kruskal-Wallis only showed differences for α-C82, keto-C84 
and keto C-86 in the lower concentration. When the Nemenyi test was applied for the 
three MAs, the ion volume was significantly higher for group ii) compared to group 
iii), and there was not significant differences in ion volume between groups ii) and i) 
or groups i) and iii) (Figure 14). 
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Figure 14. Significant differences in ion volume of individual MAs at 1 ng/10µl 
by using Nemenyi test. Number 1 and 9 identify the lower and higher ion volume 
ranking for MAs in group i) non-derivatized MAs (-) mode, group ii) non-derivatized 
MAs (+) mode and group iii) derivatized MAs (+) mode. The three dots grouped by 
color indicated the ion volume value obtained by triplicates. Brackets between 
groups indicate significant differences in ion volume.  
 
According chromatogram results derivatized samples showed a higher 
intensity compared to the non-derivatized. However, when the ion volume for the 
different MAs were analyzed, non-derivatized MAs showed a significantly higher ion 
volume. To explain this situation, the profile of derivatized and non-derivatized MAs 

























Figure 15. Ion profile comparison between derivatized and non-derivatized 
MAs in (+) mode. The arrows in box A indicate the peaks of the ion chromatogram 
(m/z 1000-1500) that were compared between derivatized (blue line) and non-
derivatized MAs (black line).  The ion profile of non-derivatized MAs in (+) mode (box 
B) and derivatized MAs (+) mode (box C) highlight in black the ions present in both 
groups. Derivatized ions are highlighted in blue and non-identified ions in derivatized 





















 The enhancement of the signal for the derivatized samples could be 
explained by the presence of derivatized compounds, non-derivatized compounds, 
and non-identified compounds that contribute to the total ion volume of the peak. 
Thus it was also important to establish the contribution in the enhancement of the 
signal of the non-identified compounds compared to the identified compounds. A 
higher (100 ng/10 µl) and a lower concentration (1 ng/10 µl) of MA standard were 
analyzed (Rt range 20-24 min) (Figure 16). 
 
 
Figure 16. Identified and non-identified compounds in Rt range 20-24 min. 
Derivatized MA standard (blue dots) and non-derivatized MA standard (black dots) at 
100ng/10µl and 1ng/10µl, and analyzed in the (+) ion mode were compared.  
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The analysis of the higher concentration of MA standard (100 ng/10 µl) 
showed a similar profile for derivatized and non-derivatized identified ions, however, 
the profile for the non-identified ions showed that derivatized samples had more 
compounds and some of them were in higher ion volume compared to the non-
derivatized MA standard. The analysis of the lower concentration (1 ng/10 µl) 
showed that identified and non-identified compounds of the derivatized samples 
were more abundant and in higher ion volume compared to the non-derivatized MA 
standard sample. Thus, non-identified compounds in the derivatized samples could 
be contributing to the enhancement of the signal displayed by the chromatogram. 
It was important to test the reproducibility of the results. To achieve this, all 
the samples were analyzed in triplicate. Higher and a lower concentrations (100 
ng/10 µl and 1 ng/10 µl for non-derivatized MAs and 100 ng/10 µl and 10 ng/10 µl for 
non-derivatized samples) were compared between derivatized and non-derivatized 
MA standard. As shown in figure 17 an evaluation of the most abundant MA species 
of each class, showed greater reproducibility for the non-derivatized samples. Higher 
concentrations of derivatized MA standard gave the greatest variability between 
triplicates. In general, higher and lower concentrations showed a similar trend in the 





















































Figure 17. Reproducibility of MAs standards. Triplicates of non-derivatized (NDV) 
MA standard in the (-) mode (A) and (+) mode (B), and derivatized (DV) MAs in the 
(+) mode (C) were compared based on ion volume. The vertical lines show the range 
of variability and the dash marks the median value. α-C78, keto-C84 and methoxy-
C85 were analyzed at a 100 ng/10 µl and a 10 ng/10 µl concentrations.  
 
7.2.1 Method detection limit of mycolic acids standard 
Method detection limit (MDL) is the minimum concentration of a substance 
that can be measured and reported to be greater than zero with 99% confidence, 
and is determined from analysis of a sample in a given matrix containing the analyte 
(Wisconsin Department of Natural Resources Laboratory Certification Program, 
Analytical detection limit guidance, 1996). To determine the MDL, different 
approaches can be used. One method consists in using the matrix (urine, water or 
other solvent) known to be free of the analyte to be investigated and analyze it 
repeatedly. The mean value represents the background and the MDL is defined as 
the statistical mean of these analyses plus 3 to 4 standard deviation units (Needlman 
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and Romberg, 1990). Another approach, and the one used in this study, utilizes 
decreasing concentrations of the analyte (MAs) in the appropiate solvent to 
determine the region of the standard curve where there is a significant change in 
sensitivity, i.e., a break in the slope of the standard curve (Wisconsin Department of 
Natural Resources, Laboratory Certification Program Analytical detection limit 
guidance, 1996). Then the overall MDL was estimated by determining the standard 
deviation (SD) across seven replicates of the concentration detected as a break in 
the slope, by multiplying the SD with the Student‘s t value for the appropriate degree 
of freedom and the 99% confidence limit (3.143 for n=7). To make the standard 
curves comparable between groups, same sets of MAs ions were used, including -
C78, -C80, -C82, keto-C84, keto-C86, methoxy-C83, methoxy-C85, and methoxy-










































Figure 18. MAs standard curve. Derivatized MAs (-) mode (A), non-derivatized 
MAs (+) mode (B), and derivatized MAs (+) mode (C). Standard curve was 







































































The MAs concentration used to determine the MDL was identified as a break 
in the slope of the standard curve corresponding to 1ng/10 l and 10 ng/10 l for 
non-derivatized and derivatized MAs respectively. After that, the MDL was estimated 
by determining the SD across seven replicates of the concentration detected as a 
break in the slope. 
To determine the background of the method, seven replicates of the blank 
chloroform: acetonitrile (2:1 v/v) for non-derivatized MAs and seven replicates of a 
blank of the derivatization reaction for the derivatized MAs were also analyzed by 
LC/MS. By using the molecular feature algorithm and the Mtb LipidDB, and AMMP 
databases no compounds that matched the Rt and m/z of the MAs in study were 
found, for this reason the background of the blank was not included in the MDL 
analysis. The data used to determine the MDL corresponded to the average ion 
volume of the seven replicates for each group in study (Table 4). 
 
Table 4. MDL (ng) for non-derivatized and derivatized MAs1 
        
Mycolic acids Non-derivatized (-) Non-derivatized (+) Derivatized (+) 
 MDL (ng) MDL (ng) MDL (ng) 
Alpha-MA (C78) 1 0.82 7.83 
Alpha-MA (C80) 0.99 0.94 6.39 
Alpha-MA (C82) 1.64 1.69 6.17 
Keto-MA (C84) 2.64 0.84 9.01 
Keto-MA (C86) 1.39 0.87 7.1 
Methoxy-MA (C83) 1.36 1.35 7.61 
Methoxy-MA (C85) 1.09 1.01 7.72 
Methoxy-MA (C87) 1.04 1 5.89 
 





The MDL varied around 1 ng/10 ul in the case of non-derivatized MAs and 
around 10 ng/10 ul for the derivatized MAs standard, equivalent to 0.15 pmol and 1.5 
pmol per 10 ul (final volume of injection for LC/MS analysis), respectively. The 
derivatization process was not able to improve the MAs sensitivity of detection.  
 
7.3 Spiking of mycolic acids in serum and urine 
Despite the fact that a significant difference in selected MAs based on the 
total ion volume of expected ions was not observed when the MAs standard was 
derivatized compared to the non-derivatized standard, it was decided to test the 
derivatization protocol for biological fluids. The rationale for this mainly pointed to 
test the feasibility of derivatization in these fluids. It was also important to establish 
extraction protocols for MAs and determine the MDL. Although spiking experiments 
of MAs in these fluids cannot be comparable to the study of clinical samples from 
individuals with active disease, this approach was intended to have an approximation 
of the behavior of MAs when they were detected by using LC/MS. 
 
7.3.1 Mycolic acids detection in urine by LC/MS  
Non-derivatized MAs spiked in urine analyzed in (+) and (-) ionization mode 
by LC/MS were compared to MAs spiked in urine that were derivatized and analyzed 
in (+) mode. Six dilutions of MAs were prepared in chloroform: methanol (2:1 v/v) in 
the range of 10 µg to 100 pg/10 µl and then dried and suspended in chloroform: 
acetonitrile (2:1 v/v). Human urine (990 µl) (Gemini- Bioproducts) was spiked with 10 
µl of the different MAs concentrations. For the lipid extraction, 3 ml of chloroform: 
methanol (2:1 v/v) was added to the urine samples. Afterwards they were vortexed 
and incubated for one hour at room temperature. HPLC grade water (0.5 ml) was 
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added and samples were centrifuged at 1,800 xg for 10 minutes, removing the upper 
layer. Following this 0.5 ml of upper Folch solution was added, and samples were 
vortexed and centrifuged at 1,800 xg for 10 minutes (x2). The chloroform fraction 
was recovered, dried under nitrogen and suspended in 51 µl of chloroform: 
acetonitrile (2:1 v/v) for the LC/MS analysis of non-derivatized MAs. For 
derivatization, MAs extracted from urine in the same manner were suspended in 10 
µl of chloroform: acetonitrile (2:1 v/v) and derivatized as described for the MA 
standard. 
The ion chromatograms for the derivatized and non-derivatized MAs spiked in 
urine were compared (Figure 19). The higher (10 ug/10 ul) and lower concentration 
(100 ng/10 ul) of urine samples spiked with MAs and derivatized, showed an 









Figure 19. Extracted ion chromatogram (1000-1500 m/z) for derivatized and 
non-derivatized MAs in urine. Results show samples analysis of 10 µg/10 µl (A) 
and 100ng/10 µl (B) in triplicate for non-derivatized MAs in (-) mode (pink line), non-




The median value for the ion volume of samples in triplicate was used to 





Figure 20. Ion volume comparisons between derivatized and non-derivatized 
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The significance of the ion volume results were analyzed using a statistical 
approach. Kruskal Wallis test (Table 5) revealed that the ion volume values were 
different between the three groups i) non-derivatized MAs in urine in (-) mode ii) 
derivatized MAs in urine in (+) mode, and iii) non-derivatized MAs in urine in (+) 
mode for 10 µg/10 µl and 100 ng/10 µl concentration. By using the Nemenyi test, 






















Table 5. Analysis of urine samples spiked with MAs by using Kruskal Wallis 
test1.  
MA (10 µg/10 µl) 
(Group i) 
Urine spiked with MAs 
(Group ii) 
Urine spiked with MAs 
(Group iii) 








Alpha-MA (C78) 10123230 (11) 19931842 (22) 14267309 (19) 
Alpha-MA (C80) 8401224 (7) 19543336 (21) 10683714 (13) 
Alpha-MA (C82) 3805365 (2) 12441092 (17) 6872939 (6) 
Keto-MA (C84) 8806390 (8) 9726614 (9) 3029084 (1) 
Keto-MA (C86) 9800682 (10) 10199467 (12) 4930313 (3) 
Methoxy-MA (C83) 5890396 (4) 10778572 (14) 6357323 (5) 
Methoxy-MA (C85) 12127571 (16) 20343990 (23) 14038446 (18) 
Methoxy-MA (C87) 11569609 (15) 21756714 (24) 14783297 (20) 
 
MA (100 ng/10 µl) 
(Group i) 
Urine spiked with MAs 
(Group ii) 
Urine spiked with MAs 
(Group iii) 








Alpha-MA (C78) 278195 (24) 171367 (20) 65599 (7) 
Alpha-MA (C80) 207676 (21) 131704 (19) 76158 (11) 
Alpha-MA (C82) 70116 (10) 65087 (6) 24967 (3) 
Keto-MA (C84) 69738 (8) 75672 (9) 11641 (1) 
Keto-MA (C86) 82626 (13) 129572 (18) 21081 (2) 
Methoxy-MA (C83) 129360 (17) 46275 (5) 46092 (4) 
Methoxy-MA (C85) 263871 (23) 85379 (14) 111265 (15) 
Methoxy-MA (C87) 211736 (22) 113345 (16) 81943 (12) 
 
1The ion volume median value for the different MAs analyzed in triplicate is shown 
(with ranks of the data in parentheses). The higher the number the greater the rank. 
MAs concentration analyzed correspond to (10 µg/10 µl) and (100 ng/10 µl) 
(α=0.05). 
  
By using the Nemenyi test for the analysis of the higher concentration of MAs 
spiked in urine (10 µg/ 10 µl), the ion volume value for the group i) was significantly 
higher compared to the group ii). There were no significant differences between 
groups i) and iii) or between groups ii) and iii) (Figure 21 A). The analysis of the 
lower MA concentration spiked in urine (100 ng/10 µl) showed that the ion volume 
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value for the group i) was significantly higher compared to group iii). There were no 
significant differences between groups i) and ii) or between groups ii) and iii) (Figure 
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Figure 21. Significant differences in ion volume between MAs spiked urine-
groups based on the Nemenyi test. Number 1 and 24 identify the lower and higher 
ion volume ranking for MAs in group i) non-derivatized MAs (-) mode, group ii) non-
derivatized MAs (+) mode, and group iii) derivatized MAs (+) mode. Brackets 
between groups indicate significant differences in ion volume. The MAs standard 
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The eight target MAs were also analyzed individually applying the same 
statistical test, and the most abundant species of each class were represented as 
shown in figure 22. Each MA was compared in i) non-derivatized (-) mode, ii) non-
derivatized (+) mode, and iii) derivatized (+) mode. The ion volume value of 
triplicates was used for each MA, considering 10 µg/10 µl and 100 ng/10 µl 
concentration. Kruskal-Wallis only showed differences for α-C82 in the higher 
concentration. When Nemenyi test was applied for α-C82, the ion volume was 
significantly higher for group i) compared to group ii), and there were not significant 
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Figure 22. Significant differences in ion volume of the α-C82 MA isolated from 
urine at 10 µg/10µl by using Nemenyi test. Number 1 and 9 identify the lower and 
higher ion volume ranking for MAs in group i) non-derivatized MAs (-) mode, group ii) 
non-derivatized MAs (+) mode, and group iii) derivatized MAs (+) mode. The three 
dots grouped by color indicated the ion volume value obtained by triplicates. 








Results were compared to establish the reproducibility between triplicates of 
derivatized and non-derivatized MAs spiked in urine (Figure 23). In general, the 
analysis of samples spiked with 10 µg/10 µl and 100 ng/10µl of MAs showed similar 
levels of variability in the measurements. An exception was the derivatized MAs at 
the higher concentration where greater variability was observed as compared to the 
non-derivatized MAs. Also in some cases, such as keto-C84, the analysis of lower 
concentrations gave an ion volume value of zero for the derivatized samples 






























Figure 23. Reproducibility of results in urine samples spiked with MAs. 
Triplicates of non-derivatized (NDV) MA standard in the (-) mode (A) and (+) mode 
(B), and derivatized (DV) MAs in the (+) mode (C) were compared based on ion 
volume. The vertical lines show the range of variability and the dash marks the 
median value. α-C78, keto-C84 and methoxy-C85 were analyzed at a 10 µg/10 µl  
and a 100 ng/10µl concentrations.  
 
 
7.3.1.1 Method detection limit of mycolic acids spiked in urine 
Standard curves were performed by spiking urine with decreasing dilutions of 
MAs in the range of 10 g to 100 pg/10 l. The ion volume values obtained through 
the MFE algorithm were plotted against the different MAs concentrations used to 

























































































Figure 24. MAs spiked in urine standard curve. Non-derivatized MAs (-) mode 
(A), non-derivatized MAs (+) mode (B), and derivatized MAs (+) mode (C). Standard 
curve was constructed by using the average ion volume of the eight-targeted MAs. 
 
 
Using the same approach applied to the MAs standards, a concentration of 
100 ng/10 ul was selected for use in determining the MDL for derivatized and non-
derivatized MAs spiked in urine. Seven replicates of the 100 ng/10 ul concentration 
were analyzed by LC/MS for the three groups (Table 6). Additionally seven replicates 
of a urine blank (990 ul urine spiked with 10 ul of chloroform: acetonitrile 2:1) in the (-
) and (+) ion modes and seven replicates of a derivatized urine blank in the (+) mode 
were also analyzed. After the MFE analysis with the Agilent MassHunter software no 
matches were found between the databases and the blanks for those MAs that were 






































Table 6. MDL (ng) for non-derivatized and derivatized MAs spiked in urine1.  
  Urine Urine Urine 
Mycolic acids 
Non-derivatized (-) 
mode MDL (ng) 
Non-derivatized (+) 
mode MDL (ng) 
Derivatized 
(+)mode MDL (ng) 
     
Alpha-MA (C78) 133.66 89.68 152.13 
Alpha-MA (C80) 131.93 95.16 82.87 
Alpha-MA (C82) 142.45 93.88 76.7 
Keto-MA (C84) 144.13 94.6 76.34 
Keto-MA (C86) 136.19 81.04 85.62 
Methoxy-MA (C83) 128.33 102.27 81.9 
Methoxy-MA (C85) 134.2 83.02 73.99 
Methoxy-MA (C87) 124.15 86.75 83.72 
 
1MDL was calculated based on the average volume value for the different MAs. 
( =0.05). 
 
The MDL was around 15.4 pmol/ 10 ul ( volume injected for LC/MS analysis) 
for the non-derivatized and derivatized MAs spiked in urine. The sensitivity 
decreased 10 fold compared to the MAs standard. There was not an improvement in 
the MDL when the derivatization method was used, but remained the same as 
compared to non-derivatized MAs. 
 
7.3.2 Mycolic acids detection in serum by LC/MS  
To assess the detection of MAs in serum six dilutions of MAs ranging from 
100 ng/10 l to 1ng/10 l in chloroform: methanol (2:1 v/v) was used to spike 90 µl of 
human serum (Sigma-Aldrich®). The MAs were extracted from the serum using a C-
18 Sep-Pak® Vac RC 100 mg cartridges equilibrated with 5 ml of methanol and 
eluted with (i) 5ml of methanol, (ii) 5 ml of methanol: n-propanol: hexane (20:4:1 v/v), 
and (iii) 5 ml of n-propanol: hexane (80:20 v/v). The third fraction containing the MAs 
was dried under nitrogen and suspended in 51 µl of chloroform: acetonitrile (2:1 v/v) 
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for LC/MS analysis in (+) and (-) ionization mode (Bhamidi et al, 2011; Sartain et al, 
2011) or derivatization and LC/MS analysis in the (+) ionization mode as described 
for the MAs standard. 
 
When the chromatograms were compared between derivatized and non-
derivatized MAs (Figure 25), the intensity of the signal was higher for the derivatized 
MAs when the range between 100 ug to 1 ug/10 ul was used to spike the serum. 
From the 100 ng/10 ul concentration the signal for the derivatized compounds 











Figure 25. Extracted ion chromatogram (m/z 1000-1500) of derivatized and non-
derivatized MAs spiked in serum samples. Different concentrations of MAs at 100 
µg/10 µl (A) and 1µg/10 µl (B) were used to spike human serum. Results (in 
triplicate) are shown for non-derivatized serum samples spiked with MAs in (-) 
ionization mode (pink line) and (+) ionization mode (black line) and derivatized 





The median ion volume value of the eight target MAs were compared (Figure 
26). The MAs (100 ug/10 ul) ion volumes obtained for the non-derivatized sample 
analyzed in the (-) or (+) ion mode were approximately 20 to 30 fold lower as 
compared to the samples subjected to derivatization prior to LC/MS  (Figure 26 A). 
When lower concentrations were analyzed, the volume of the derivatized MAs was 3 

















Figure 26. Ion volume comparison between derivatized and non-derivatized 
MAs spiked in serum. The median values of the triplicate analyses of serum spiked 
with 100 ug/10ul (A) or 1 ug/10ul (B) were used to construct the graphs.  
 
As with the MA standards and the spiked urine samples the median ion 
volume values presented in Figure 26 were used to perform a Kruskal Wallis test 
(Table 7) to rank each MA measurement and these data applied to a Nemenyi test to 
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Table 7. Analysis of serum samples spiked with MAs by using Kruskal Wallis 
test1.  
MA (100 µg/10 µl) 
(Group i) 
Serum spiked with 
MAs 
(Group ii) 
Serum spiked with 
MAs 
(Group iii) 









Alpha-MA (C78) 1159302 (16) 286290 (6) 28821423 (23) 
Alpha-MA (C80) 890002 (15) 253153 (5) 21397593 (21) 
Alpha-MA (C82) 248844 (4) 151559 (2) 7017985 (17) 
Keto-MA (C84) 380490 (11) 286623 (7) 8046120 (18) 
Keto-MA (C86) 211813 (3) 77661 (1) 8314938 (19) 
Methoxy-MA (C83) 395646 (12) 320398 (8) 14380284 (20) 
Methoxy-MA (C85) 864907 (14) 344723 (9) 30210000 (24) 
Methoxy-MA (C87) 678461 (13) 378603 (10) 22456988 (22) 
 
MA (1 µg/10 µl) 
(Group i) 
Serum spiked with 
MAs 
(Group ii) 
Serum spiked with 
MAs 
(Group iii) 









Alpha-MA (C78) 710829 (18) 626153 (16) 2304858 (23) 
Alpha-MA (C80) 693604 (17) 402061 (12) 1695401 (21) 
Alpha-MA (C82) 245397 (8) 151309 (5) 731996 (19) 
Keto-MA (C84) 202948 (7) 179919 (6) 436473 (13) 
Keto-MA (C86) 77652 (1) 147631 (4) 595882 (15) 
Methoxy-MA (C83) 131337 (3) 126267 (2) 870334 (20) 
Methoxy-MA (C85) 388556 (11) 382219 (10) 2390037 (24) 
Methoxy-MA (C87) 554727 (14) 360073 (9) 1778593 (22) 
 
1The median ion volume value from derivatized and non-derivatized triplicates of 
MAs is shown (with ranks of the data in parentheses). The higher the number the 
greater the rank. MAs concentrations analyzed correspond to 100 ug/10 ul and 1 
ug/10 ul (α=0.05). 
 
Nemenyi test applied to the data from the higher concentration of MAs spiked 
in serum (100 µg/ 10 µl), the ion volume value for the group iii) was significantly 
higher compared to the group i) and ii). There were no significant differences 
between groups i) and ii) (Figure 27 A). The analysis of the lower MA concentration 
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spiked in serum (1 µg/ 10 µl) showed that the ion volume value for the group iii) was 
significantly higher compared to group i) and ii). There were no significant 
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Figure 27. Significant differences in ion volume between MAs spiked in serum-
groups based on the Nemenyi test. Number 1 and 24 identify the lower and higher 
ion volume ranking for MAs in group  i) non-derivatized MAs (-) mode, group ii) non-
derivatized MAs (+) mode, and group iii) derivatized MAs (+) mode. Brackets 
between groups indicate significant differences in ion volume. The MA standard 
concentrations spiked in serum were 100 µg/ 10 µl (A), and 1 µg/ 10 ul (B).  
A 
B 
Group iii  
Group ii  
Group i 
Group iii  





 As with the MA standards and the spiked urine, it was important to 
compare individually the targeted MAs. The ion volume of the triplicate analysis were 
applied to the Kruskal-Wallis test for the eight targeted MAs and three groups i) MAs 
non-derivatized (-) mode, ii) MAs non-derivatized (+) mode, and iii) MAs derivatized 
(+) mode were compared for each targeted MA. . Significant differences between 
groups were found only in the 100 µg/10 µl concentration for α-C78, methoxy-C85 
and methoxy C-87. These three MAs were subjected to Nemenyi test to identify 
those differences (Figure 28). The analysis showed same results for the three MAs 
with a significantly higher ion volume for group iii) compared to group ii). There were 
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Figure 28. Significant differences in ion volume of individual MAs at 100 
µg/10µl by using Nemenyi test.  Number 1 and 9 identify the lower and higher ion 
volume ranking for MAs in group  i) non-derivatized Mas (-) mode, group ii) non-
derivatized MAs (+) mode, and group iii) derivatized MAs (+) mode. The three dots 
grouped by color indicated the ion volume value obtained by triplicates. Brackets 







The reproducibility of the results was also tested. 100 µg/10 µl and 100 ng/10µl 
concentrations were analyzed for non-derivatized MAs and 100 µg/10 µl and 1µg/10 
µl for derivatized MAs (Figure 29). The analysis of the different concentrations 
showed a similar trend in the variability of the measurements. However, the 
variability between triplicates was higher for the non-derivatized MAs in (+) mode. 
Lower concentrations were not compared because zero values were common to be 
found between the triplicates and the presence of three values to establish 






























Figure 29. Reproducibility of results in serum samples spiked with MAs 
standard. Triplicates of non-derivatized (NDV) MA standard in the (-) mode (A) and 
(+) mode (B) and derivatized (DV) MAs in the (+) mode (C) were compared based on 
ion volume. 
 
7.3.2.1 Method detection limit of mycolic acids spiked in serum 
The standard curves for MAs in serum were constructed by using six MAs 
concentrations ranging between 1 ng/ 10 ul and 100 ug/ 10 ul. A break in the slope 
was observed at 100 ng/10 l for non-derivatized MAs in (+) and (-) and 1 ug/ 10 ul 


























































































Figure 30. Standard curve of MAs spiked in serum. Non-derivatized MAs (-) 
mode (A), non-derivatized MAs (+) mode (B), and derivatized MAs (+) mode (C). 
Standard curve was constructed by using the average ion volume of the eight 
targeted MAs. 
 
For the MDL seven replicates of the mentioned concentrations were analyzed 
by LC/MS in the respective ionization mode. To determine the background noise of 
the method, seven replicates of a serum blank (90 ul o serum spiked with 10 ul of 
chloroform: acetonitrile (2:1 v/v)) for non-derivatized MAs and seven replicates of a 
serum blank of the derivatization reaction were also analyzed by LC/MS. By using 
the MFE algorithm and the Mtb LipidDB and AMMP-MA databases, no matches 
between the different blanks and the MAs studied were found (including m/z and 






































Table 8. MDL (ng) for non-derivatized and derivatized MAs spiked in serum1.  
  Serum Serum Serum 
Mycolic acids Non-derivatized (-)  Non-derivatized (+) mode Derivatized (+) mode 
  mode MDL (ng) MDL (ng) MDL (µg) 
Alpha-MA (C78) 99.66 21.89 0.9 
Alpha-MA (C80) 101.77 56.24 0.92 
Alpha-MA (C82) 119.71 42 0.9 
Keto-MA (C84) 164.96 108.99 0.86 
Keto-MA (C86) 178.77 23.57 0.95 
Methoxy-MA (C83) 108.48 29.18 0.88 
Methoxy-MA (C85) 129.94 56.61 0.82 
Methoxy-MA (C87) 121.16 30.11 0.67 
 
1MDL was calculated based on the average ion volume value for the different MAs. 
( =0.05). 
 
 The MDL was around 15.4 pmol/ 10 ul (final volume of injection for LC/MS 
analysis) for non-derivatized MAs in (+) and (-) ionization mode and 154 pmol/ 10 ul 
for the derivatized MAs in the (+) mode. The derivatization protocol did not improve 
the limit of detection, following the same trend as before. Regarding the non-
derivatized MAs, the MDL sensitivity was 100 fold higher compared to the MAs 










8. Discussion and conclusions 
 The limited sensitivity of diagnostic TB tests causes special concern in some 
world areas and population groups, triggering numerous studies to discover and 
evaluate biomarkers. The goal of this study was to generate a more sensitive 
method for the detection of MAs. Available information about the TB cell wall 
composition linked several of its compounds to virulence and resistant roles; with the 
MAs exhibiting unique characteristics that support targeting them as a feasible 
biomarker for TB. The MAs have been analyzed directly from TB cultures to identify 
and classify mycobacterial species by HPLC (Butler et al., 2001); analyzed from 
sputum samples by LC/MS (Minnikin et al., 1993; Shui et al., 2011) and were 
targeted for serological studies (Ryll et al., 2001). However, there are no previous 
studies that can corroborate the presence of MAs in serum or urine samples from 
Mtb infected patients. 
 As a first step in determining the feasibility of serum or urine MAs as a 
biomarker of TB, this study was performed to develop and evaluate for MA detection 
by LC/MS. Specifically a pre-existing derivatization protocol was modified to make it 
amenable to the hydrophobic nature of MAs. Other derivatization protocols to 
improve MA detection have been previously investigated. The formation of MA 
methyl esters (MAMEs) allows a better separation by TLC (Minnikin et al., 1984). 
Fluorescent derivatives have been also used for HPLC analysis (Minnikin et al., 
1993). The goal of the derivatization protocol used in our study looked for an 
improvement of the detection sensitivity by increasing the ionization efficiency of 
MAs by adding a quaternary amine to improve ionization efficiency leading to an 
increased signal when analyzed by LC/MS. The attachment of a quaternary amine to 
fatty acids between 24 and 30 atoms carbon residues increases the ionization 
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efficiency 2,500 fold (Yang et al, 2007).  
To assess whether the Yang et al. (2007) methodology could be applied to 
MAs, these studies first identified a solvent system that was compatible with MAs 
and the derivatizing reagents, and established a protocol that removed excess 
derivatizing reagents or by products prior to analysis by LC/MS. This effort resulted 
in identifying chloroform/acetonitrile (2:1) as an appropriate derivatizing solvent and 
acetonitrile as an effective method to remove excess derivatizing reagents or by 
products. Importantly, this basic method development endeavor highlighted the 
importance of selecting derivatizing reagents that have similar solubility to the 
targeted fatty acids and that will not interfere with downstream measurements.  
To fully evaluate the effectiveness of the derivatization protocol and detection 
of products by LC/MS the ion volume values of eight targeted MAs were used to 
compare the derivatized and non-derivatized samples of MA standards, and urine 
and serum spiked with the MA standards. The statistical analyses of the data 
included using the median value of triplicate analyses to establish a ranking of the 
use of (-) and (+) ionization mode LC/MS to measure underivatized MAs versus (+) 
ionization mode LC/MS to measure derivatized MAs. Additionally, multiple 
concentrations of MAs were assessed as underivatized samples in the (-) and (+) 
ionization modes and as derivatized in the (+) ionization mode to establish relative 
MDL of each process. Further, analyses included detailed inspection of the LC/MS 
data and evaluation of the variability in data for each process or sample group. 
In the case of the MAs standard and urine samples spiked with MAs, the ion 
volume values for the targeted MAs of the non-derivatized samples were higher 
compared to the derivatized samples. The Kruskal-Wallis and Nemenyi test (Zar, 
1999) for ranking of the groups consistently showed that the non-derivatized 
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samples analyzed in (+) or (-) ion modes were significantly higher than the 
derivatized samples. These statistical analyses of targeted MAs, however, did not 
correlate to the ion chromatograms where the derivatized samples showed a 
consistently a higher signal of detection. Detailed comparative analyses of the MS 
data for the MA standard shed some light on to this discrepancy. When different 
peaks of derivatized and non-derivatized samples were compared in the (+) mode, 
the ion profiles showed that the total signal of the peak for the derivatized samples 
was comprised of derivatized MAs, non-derivatized MAs and non-identified 
compounds. Moreover, the non-identified compounds in the derivatized MAs 
standard samples showed to be more abundant and in higher ion volume compared 
to the non-derivatized. These two factors could be explaining the increase of the total 
signal, leading to an enhancement of the peaks in the chromatogram profile, but a 
decreased ion volume value for targeted MAs. These observations were also 
consistent with the variability in reproducibility between sample groups (derivatized 
versus underivatized) for ion volume measurements for the eight targeted MAs. This 
increase in variability of data was most evident for derivatized MAs standard and 
derivatized MAs spiked in urine when the higher concentrations of MAs were 
evaluated. 
The presence of non-derivatized MAs in the derivatized sample and the ion 
volume variability could be explained by the use of non-polar solvents that can affect 
in some way the solubilization of the derivatizing reagents. Additionally, a cleaning 
step applied after the derivatization was necessary to avoid an excess of reagents 
that could affect the performance of the mass spectrometer. However this process, 
could also affect the final available amount of derivatized MAs to be analyzed by 
LC/MS. The incubation period of the derivatization reaction and temperature could 
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be two factors susceptible to modification to achieve better derivatization efficiency 
(Duong et al., 2012). 
Serum samples spiked with MAs, however, yielded an unexpected result. 
When higher concentration of MAs were compared (100 μg/10 μl) the total ion 
volume for the targeted mycolates was increased 20 to 30-fold for the derivatized 
samples as compared to the non-derivatized samples. The peak intensity in the 
chromatogram was also higher compared to non-derivatized serum samples. When 
variability between triplicates analyses was evaluated there was higher variability in 
the ion volumes for the non-derivatized MAs analyzed in the (+) mode. This points to 
a phenomenon where the MAs may actually derivatize more efficiently in the 
presence of serum components. It has been suggested that an interaction between 
cholesterol and MAs could influence the low sensitivity of serological TB tests when 
free MAs are used in an ELISA assay (Benadie et al., 2008). Additionally, when MAs 
were converted into their methyl ester derivatives conformational changes occur in 
the MAs and this prevents the binding of cholesterol to the MA structure (Benadie et 
al., 2008).It is speculated that compounds present in the human serum such as 
cholesterol coelute with the MAs during the enrichment step with C18 cartridges. It is 
possible that the addition of a quaternary amine through the derivatization could in 
some way counteract an interaction between MAs and serum components that could 
be suppressing or inhibiting the ionization of the MAs in the non-derivatized samples. 
This would lead to appearance of increased detection in the derivatized sample. 
Alternatively, it can also be hypothesized that the interaction of the MAs with a serum 
product could increase derivatization efficiency by making the carboxylic acid more 
accessible for derivatization. It is interesting to note that when lower concentration of 
MAs spiked in serum were analyzed (1 ng/10 μl, 10 ng/10 μl), the ion volume value 
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for the derivatized MAs decreased compared to the non-derivatized samples. In this 
case, we expect that fatty acids compounds present in serum could be competing 
with MAs in the derivatization process, and diminishing the derivatization efficiency 
for MAs compounds. It is also possible that the extraction procedures for isolation of 
the MAs from the serum need to be further optimized. 
The MDL of derivatized and non-derivatized MAs by using LC/MS was also 
calculated. It was important to evaluate the sensitivity of the method and compared it 
to biological fluids spiked with the MA standard. Shui et al., (2007) used LC/ESI-MS 
to compare the lipid profiles of mycobacteria grown under different physiological 
conditions. MAs were analyzed in (-) ionization mode and the limit of detection 
(signal/ noise 3) was estimated to be 10 pmol. In another study performed by Laval 
et al., (2001), by using MALDI-TOF in (+) ionization mode, less than 10 pmol of 
mycolates was sufficient to obtain adequate MA mass spectra. These results are in 
concordance to the MDL obtained in this study where the MDL for the MA standard 
was 0.15 pmol. In the case of non-derivatized samples, serum and urine spiked with 
MAs showed and increased MDL of 100-fold compared to the MA standard. This 
situation was expected because of the lipid extraction process and the more complex 
nature of the samples. After the derivatization process, the MA ion volumes were 
compared to their respective non-derivatized MAs, and resulted in the MDL being 
increased 10-fold for the derivatized MA standard and MAs in serum. However, the 
derivatized and non-derivatized MAs in urine were found to have the same MDL. 
These data indicate that the derivatization process did not improve the MDL. 
The MDL was determined by using the concentration that produced a break in 
the slope of the standard curve of MAs. It is important to consider that the higher 
MDL obtained for the derivatized MAs was reflected in a more abrupt dropped of the 
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detection signal between the 10 μg and the 1μg. There is subjectivity in this 
approach since with both the derivatized and underivatized samples two different 
slopes and two break points could be observed for some of the MAs. The use of the 
most consistent break point for all the targeted MAs typically lead to the selection of 
a higher concentration of MAs being used to calculate the MDL for the derivatized 
samples. 
The analytical sensitivity can be defined as the smallest amount of a 
substance in a sample that can be accurately measured by an assay. This has to be 
differentiated from the diagnostic sensitivity that indicates the percentage of infected 
individual identified as positive by the technique (Saah et al, 1997). During this study 
just the analytical sensitivity could be estimated through the MDL, because no 
clinical samples from infected Mtb patients were include. 
The noise was not considered in the MDL because there were not ions with the 
same mass or Rt that the MAs included in this study. Despite this, other ions 
detected at the same Rt, but with different mass can be exerting a matrix 
suppression effect over the MAs in study, affecting the MAs MDL and the analytical 










9. Future directions 
 It is difficult to estimate the applicability of LC/MS for MA detection in serum or 
urine. The first approach would be having a proof of principle of their presence in 
clinical samples from infected Mtb patients, and having an adequate standard to 
quantify the presence of the different MAs. Previous studies have confirmed the 
presence of MAs in sputum from Mtb infected patients (Minnikin et al., 1993, Shui et 
al., 2011). Shui et al., (2011) analyzed sputum samples from Mtb infected patients by 
multiple reaction monitoring (MRM). By using this technique a precursor ion of 
interest is selected in the first mass analyzer of a tandem mass spectrometer and 
fragmented in the collision cell, then a characteristic product ion is selected in the 
second mass analyzer, providing a quantitative analysis. This method was compared 
to AFB smear and bacterial culture, giving a 100% of accuracy when was compared 
to smear (+++) and (++), 97.5% for smears (+) and 25% for smear (-)/culture (+). It 
could be inferred that by using MRM, the sensitivity of the method can be improved 
for the detection of MAs in other fluids such as serum and urine. However, it would 
be important to consider adequately the precursor ions because the MA profile may 
vary.  
 Shui et al., (2011) showed the major ions identified in clinical sputum samples 
were α-MA m/z 1164 (C80), methoxy-m/z 1280 (C87), and keto-m/z (C86) compared 
–m/z 1136 (C78), methoxy-m/z 1252 
(C85), and keto-m/z 1236 (C84) were the most abundant. Bhamidi et al., 
(unpublished data) analyzed granuloma from Mtb infected guinea pigs by LC/MS 
showing a MA profile with predominance of even-numbered α-MAs (C78, C80, C82), 
but also new findings from a few granulomas reported identifying odd-numbered 
carbon α-MAs in the same or higher abundance than even-numbered α-MAs and the 
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presence of short chain α-MAs (α‘) for some granulomas. This uncommon profile 
with odd α-MAs and α‘-MAs was also found in sputum samples from Mtb infected 
patients. Even though the α-mycolate class appears to be predominant during the 
analysis of in vitro and in vivo Mtb, the total profile in biological samples can vary, 
reflecting unique situations during the disease process. 
 More studies including clinical samples from Mtb infected patients are 
necessary to determine MAs pattern profiles. In the case of using LC/MS for the 
samples analysis, it could be important to analyze them by using (-) and (+) 
ionization mode, to cover a broader spectrum, identifying the most common 
compounds. By having the clinical story of the patient, valuable information could be 
obtained from changes in the MA profile during the course of the disease, and during 
a treatment regimen. 
 In the field of biomarkers, LC/MS is a sensitive method to evaluate serial 
molecules. However, in terms of expertise, management, and cost it is restrictive. If 
the proof of principle of MAs detection in serum and urine is confirmed, the next 
steps would be the development of a more portable and less expensive platform for 
identification. In the field of biomarkers some possibilities have been explored, 
cardiac biomarkers can be identified by using cleavable tag immunoassays, where 
the fluorescent tag is cleaved from the detection antibody and analyzed by using a 
microchip through a chromatographic technique (Caulum et al., 2007). Tagging 
immunoassay for MAs could be challenging in terms of specificity, because lipids are 
poor immunogens (Gargir et al., 2002). However, Fujiwara et al., (1999) immunized 
rabbits with Mtb cord factor (trehalose-6, 6‘-dimycolate), showing that their sera 
reacted especially against methoxy-MAs derivatives; it was also concluded that the 
IgG antibody recognized the hydrophobic moiety rather than carbohydrate moiety of 
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the cord factor structure. Considering these results, it is possible to think that MAs 
can be targeted more specifically. 
 Fluorescent tagging has also been used for MA detection. Theoretically, 
fluorescence detection could increase the sensitivity 10 to 1,000 times (Butler et al., 
2001). Minnikin et al., (1993), used HPLC to achieve a characteristic profile for the 
fluorescent anthrylmethyl ester MA derivative. Fluorescent tagging however, can be 
expected to be unspecific in the presence of other fatty acids, such as in a serum 
sample. The highly hydrophobic nature of MAs could be exploited to make the 
detection more specific, for example using fluorescence TAG, and then capturing 
MAs by using C18 cartridges.  
 Regarding the study of MAs in serum or urine, there is no precise information 
about the release or clearance of these molecules. It can be speculated that MAs, as 
in the case of LAM (Boehme et al., 2005), could be released from TB bacterial cells, 
reaching the circulatory system and filtered by the kidneys, this idea could be a 
possible explanation for the hypothesis that MAs can be encountered in serum and 
urine from infected patients. Ojha et al., (2010) showed the presence of free MAs in 
M. smegmatis biofilms, generated from the enzymatic activity of a specific TDM 
serine esterase. They also suggested the presence of a TDM specific esterase in 
Mtb. This could be another way to expect free MAs available to be detected. 
 Bacteremia or renal TB could be possible situations where serum or urine 
samples may be assimilated to the sputum sample behaviour, due to the proximity to 
the infectious focus. Urogenital TB is responsible for 30 to 40 % of the 
extrapulmonary cases and is second to the lymph-node extrapulmonary presentation 
(Figueiredo et al., 2008). In the case of the bacteremia, it became more common 
with the emergence of patients with AIDS (Grinsztejn et al., 1997). In a study 
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performed by Thambu et al., (2004), 43% of HIV-infected infected patients (n=20) 
had bacteremia detected by culture of blood samples. Another study in Brazil, 
investigated the prevalence of bacteremia in patients with HIV and with persistent 
fever by using automated blood. 30% (n=13) of the cases were confirmed as 
positives (Bacha et al., 2004). Regarding the lower sensitivity of smear microscopy in 
AIDS patients, and the presence of bacteria in blood, detection in serum appears as 
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LIST OF ABBREVIATIONS 
 
 
AFB                                                          
AG                                                             
AIDS                                                          
AMMP                                                       
amu                                                           
APCI                                                         
AraLAM                                                     
BMP                                                           
CDR                                                           
CMP                                                           
CSF                                                           
DAP                                                           
DAT                                                           
DBP                                                            
DOTS                                                         
DTH                                                            
EI                                                                
ELISA                                                         
ELISPOT                                                    
EMB                                                           
ES                                                             
ESI                                                             
FM                                                             
GC                                                             
GLU                                                           
HAART                                                      
HIV                                                            
HPLC                                                         
IFN-γ                                                         
IGRAs                                                        
IL  
INH   
IS    
katG    
LAM   
LC    
LM    
LTBI    
LAMP    
MAMEs    
MHC    
ManLAM    
MS    
MALDI       
Acid-fast bacilli 
Arabinogalactan Arabinomannan 
Acquired immune deficiency síndrome 
3-acyl-oxymethyl-1-methylpyridinium iodide  
Atomic mass units 
Atmospheric pressure chemical ionization  
Arabinan of Lipoarabinomannan  
2-Bromo-1-methylpyridinium Iodide  
Case detection rate  
3-Carbinol-1-methylpyridinium Iodide  
Cerebrospinal fluid  
Diaminopimelic acid  
Diacyltrehaloses  
D binding protein precursor  
Directly observed treatment short course  
Delayed-type hypersensitivity  
Electron impact  
Enzyme-linked immunosorbent assay  
Enzyme-linked immunospot  
Ethambutol  
Electrospray  
Electrospray ionization  
Foamy macrophages  
Gas chromatography  
Glucane  
Highly active antiretroviral therapy 
Human immunodeficiency virus  
High-performance liquid chromatography  
Gamma interferon  
Interferon-gamma  release assays  
Interleukin  
Izoniacid 
Insertion sequence  
Catalase peroxidase enzyme  
Lipoarabinomannan  
Latent tuberculosis infection   
Lipomannan  
Liquid chromatography  
Loop-mediated isothermal amplification  
Mycolic acid methyl esters  
Major histocompatibility complex  
Mass spectrometry  
Mannose lipoarabinomannan 
Matrix assisted laser desorption/ionization  
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MDL    
MAC  
Max 
min   
MFE   
MDR   
Mtb   
MTD   
msl   
Magp    
Mas    
NK    
NTM    
NAA    
OD    
PAT    
PG     
PGLs     
PIMs    
PE    
PAT    
PDIMS    
PILAM   
pks   
PPD    
PZA   
RIF   
SDS    
SD   
SL    
TLC   
TLR   
tr-DNA   
TDM   
TAT     
TEA 
TST   
TSA    
TB     
TNF   
TAT    
VOCs    
WHO    
XDR    
Method detection limit  
Mycobacterium avium complex 
Maximum  
Minimal  
Molecular Feature Extraction 
Multidrug-resistance  
Mycobacterium tuberculosis  
Mycobacterium Tuberculosis Direct 
Mycocerosic acid synthase like gene  
Mycolic acid-peptidoglyca arabinogalactan 
Mycolic acids 
Natural killer  
Nontuberculous mycobacteria  
Nucleic acid amplification 
Optical density  
Pentaacyl trehalose  
Peptidoglycan  
Phtiocerol dimycocerosates  
Phosphatidil inositol manosside  
Phosphatidylethanolamine  
Polyacyltrehaloses  
Phenol glycolipids  
Lipoarabinomannan inositol phosphate 
Polyketide synthase  
Purified protein derivative  
Pyrazinamide  
Rifampicin  
Sodium dodecyl sulfate  
Standard deviation  
Sulfolipid 
Thin layer chromatography  
Toll-like receptor  
Transrenal DNA  
Triacyltrehaloses  
Trehalose 6, 6‘- dimycolate  
Triethylamine  
Tuberculin skin test  
Tuberculoestearic acid  
Tuberculosis  
Tumour necrosis factor  
Turn around time  
Volatile compounds  
World Health Organization  
Extensively drug-resistant 
 
 
 
 
